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1. Introduction 
Since 2000, 11 External Quality Assurance System (EQAS) reports have been issued with this 
report being the 12th
The EQAS is organized annually by the Technical University of Denmark, National Food Institute 
(DTU Food), Kgs. Lyngby, Denmark in collaboration with Centers for Disease Control and 
Prevention (CDC) in Atlanta, USA; World Health Organization (WHO) in Geneva, Switzerland; 
Public Health Agency of Canada (PHAC) in Canada; National Salmonella and Shigella Center 
(NSSC), National Institute of Health, Department of Medical Science in Thailand and Institute 
Pasteur (IP) in Paris, France. The technical advisory group for the WHO EQAS program consists of 
members of the WHO GFN Steering Committee.  
. The WHO Global Foodborne Infections Network (WHO GFN), focuses on 
enhancing World Health Organization (WHO) Member States’ capacity to detect and respond to 
foodborne disease outbreaks by conducting laboratory-based surveillance of Salmonella and other 
foodborne pathogens. Since its inception, the scope of WHO GFN has expanded to include 
additional foodborne pathogens like Shigella and Campylobacter. Salmonella, Campylobacter and 
Shigella are among the most important foodborne pathogens worldwide and account for millions of 
cases of diarrheal disease and thousands of deaths per year, impacting both developing and 
industrialized countries. Furthermore, the increased number of Salmonella and Shigella isolates 
which are resistant to antimicrobials is of major concern since these isolates are associated with 
infections characterized by increased morbidity and mortality. 
Individual laboratory data are confidential and only known by the participating laboratory, the 
EQAS Organizer (DTU Food) and possibly the respective WHO GFN regional centre. All summary 
conclusions are made public. The goal set by WHO GFN aim towards having all national reference 
laboratories perform Salmonella serotyping with a maximum of one deviation out of eight strains 
tested (error rate of 13%) and antimicrobial susceptibility testing (AST) with a maximum error rate 
of 10% (either <5% very major / major errors and <5% minor errors, or <10% minor errors, as 
defined further in this report). No quality threshold has been determined in relation to identification 
of Campylobacter ssp., serotyping and AST of Shigella, or identification of the unknown foodborne 
pathogen. 
 
2. Materials and Methods 
A pre-notification announcement of the EQAS 2012 was made through the WHO GFN list server 
on May 2
2.1 Participants 
nd, 2012 and a reminder was sent on May 24th, 2012 (App. 1). The pre-notification was 
available in English, Spanish, Portuguese, French, Chinese and Russian, and included invitations to 
participate in the EQAS 2012 program for serotyping and AST of Salmonella and Shigella, 
identification and AST [Minimum Inhibitory Concentration (MIC) determination] of 
Campylobacter, and identification of an unknown foodborne pathogen. Participation was free of 
charge, but each laboratory was expected to cover expenses associated with the analyses performed.  
Eight Salmonella strains, four Shigella strains, and two Campylobacter strains were selected for the 
EQAS 2012 from the DTU Food’s strain collection. The unknown foodborne pathogen, a 
Salmonella Paratyphi B var. Java strain, was selected by the Laboratory Subcommittee under the 
WHO GFN Steering Committee, and was selected from the strain collection at DTU Food. 
Individual sets of Salmonella, Shigella, and the unknown strain for identification were inoculated as 
agar stab cultures in nutrient agar. The Campylobacter strains were lyophilized in glass vials by 
2.2 Strains 
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Czech Collection of Micro-organisms (CCM), Czech Republic. The serotype of each Salmonella 
strain was determined based on the O (somatic), phase 
Laboratories which did not formerly participate in the WHO GFN EQAS AST component were 
provided with lyophilized international reference strains, namely E. coli CCM 3954 ~ American 
Type Culture Collection (ATCC) 25922 and C. jejuni CCM 6214 ~ ATCC 33560, purchased from 
the Czech Collection of Micro-organisms (CCM); The Czech Republic. 
1 and phase 2 H (flagellar) antigens 
according to the scheme of Kaufmann-White (2007) [1]. The Salmonella serotypes were determined 
by DTU Food and verified by the CDC and IP prior to distribution. The antimicrobial susceptibility 
patterns of the Salmonella, Shigella and Campylobacter strains were determined by DTU Food and 
verified by CDC. The Shigella serotypes were performed by PHAC and verified by the NCCS. A 
final confirmation after production of agar sticks was performed at DTU Food (apart from Shigella 
serotyping which is not routinely performed at DTU Food). 
AST of the Salmonella, Shigella, and Campylobacter strains was performed at the DTU Food, and 
the obtained results were used as a reference standard (App. 2). The following antimicrobials were 
used for AST of Salmonella and Shigella strains: ampicillin, AMP; cefotaxime, CTX; ceftazidime, 
CAZ; ceftriaxone, CRO; chloramphenicol, CHL; ciprofloxacin, CIP; gentamicin, GEN; nalidixic 
acid, NAL; streptomycin, STR; sulfamethoxazole, SMX; tetracycline, TET; trimethoprim, TMP and 
trimethoprim + sulphonamides, SXT. In addition, it was possible to confirm the presence of 
Extended Spectrum Beta-Lactamase (ESBL)-producing strains by using the antimicrobials CTX 
and CAZ in combination with the inhibitor clavulanic acid. The following antimicrobials were used 
for AST of Campylobacter strains: chloramphenicol, CHL; ciprofloxacin, CIP; erythromycin, ERY; 
gentamicin, GEN; nalidixic acid, NAL; streptomycin, STR; and tetracycline, TET. 
2.3 Antimicrobials 
MIC determination was performed by using Sensititre systems from Trek diagnostics Ltd, and 
guidelines and breakpoints by Clinical and Laboratory Standards Institute (CLSI) based on 
document M07-A9 (2012) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically”; Approved Standard - Ninth Edition [2], M100-S22 (2012) “Performance 
Standards for Antimicrobial Susceptibility Testing”; Twenty-Second Informational Supplement [3], 
document M31-A3 (2008) “Performance Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated from Animals”; Approved Standard - Third Edition [4], 
and document M45-A2 (2010) “Methods for Antimicrobial Dilution and Disk Susceptibility Testing 
of Infrequently Isolated or Fastidious Bacteria”; Approved Guideline – Second Edition [5]. 
Guideline were used for interpretation of AST results with the exception of i) ciprofloxacin 
susceptibility testing for which the EUCAST (European Committee on Antimicrobial Susceptibility 
Testing; www.eucast.org) epidemiological cut-off value was utilized; ii) streptomycin susceptibility 
testing for which DTU Food interpretative criteria was utilized; and iii) Campylobacter AST, for 
which EUCAST epidemiological cut-off values were used. For cefotaxime, ceftazidime and 
ceftriaxone values listed in CLSI M100-S22, Table 2A Supplemental Table 1 were utilized. All 
breakpoints are listed in the protocol (App. 3). 
Bacterial cultures were enclosed in double pack containers (class UN 6.2) and sent to participating 
laboratories according to the 
2.4 Distribution 
International Air Transport Association (IATA) regulations as 
“Biological Substance category B” classified UN3373. Prior to shipping, laboratories were 
informed about the dispatch date. Import permits were necessary for shipping the parcels to a 
number of countries. Many of the parcels were shipped as “overpack” through international hubs 
which offered to support the costs of further distributing the parcels. Helen Tabor from PHAC; 
 7 
Canada, Matt Mikoleit from CDC; United States, Chaiwat Pulsrikarn from NSSC; Thailand, 
Francois Xavier Weill from IP; France, Marcelo Galas from ANLIS “Dr. Carlos G. Malbrán”; 
Argentina, Rita Tolli from Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana, 
Italy and Rama Murthy from National Institute of Cholera and Enteric Diseases, India shipped to all 
Canadian, American, Thai, Francophone African, South American/Caribbean, Italian and Indian 
institutes, respectively. From China, agreements were in place to send an overpack to Kan Biao 
from Institute for Communicable Disease Prevention and Control, Beijing. Most parcels were 
dispatched in August-September 2012. 
Participants were instructed to download the protocol (App. 3) and additional documents; 
“Subculture and Maintenance of quality control (QC) strains” and “Instructions for opening and 
reviving lyophilized cultures” (App. 4a and 4b; available only in English) from 
2.5 Procedure 
http://www.antimicrobialresistance.dk/. In addition, they were requested to subculture the strains 
prior to performing the method routinely used in their laboratory. The EQAS components included 
serotyping and AST of eight Salmonella and four Shigella strains, identification and MIC 
determination of two Campylobacter strains, AST of two QC strains (E. coli CCM3954 / 
ATCC25922, C. jejuni CCM 6214 / ATCC33560), and identification of an unknown foodborne 
pathogen (Salmonella Paratyphi B var. Java). Furthermore, the laboratories were requested to save 
and maintain the ATCC reference strains for future proficiency tests (App. 4a and 4b). 
After performing the tests, participants were requested to submit i) the obtained results (serogroup 
and / or serotype, MIC values or zone-diameter in millimeters, and antimicrobial susceptibility 
categories of the Salmonella and Shigella strains; ii) identification, MIC values, and antimicrobial 
susceptibility categories of the Campylobacter strains; iii) identification of the unknown strain). The 
results were to be submitted to an electronic record sheet in the WHO GFN web-based database 
through a secured individual login, or alternatively, to send the record sheets from the enclosed 
protocol by fax to DTU Food. The database was activated on October 12th, 2012 and closed on 
June, 10th
The Salmonella and Shigella strains were categorized as resistant (R), intermediate (I) or 
susceptible (S) to all tested antimicrobials, whereas the Campylobacter strains were categorized as 
resistant (R) or susceptible (S) to all tested antimicrobials. The interpretative criteria followed to 
generate the results used as reference standard were based on both clinical breakpoints and 
epidemiological cut-off values as described above. 
, 2012. 
Of note, the authors would like to state that the terms ‘susceptible’, ‘intermediate’ and ‘resistant’ 
should be reserved for classifications made in relation to the therapeutic application of antimicrobial 
agents. When reporting data based on epidemiological cut-off values, bacteria should instead be 
reported as ‘wild-type’ or ‘non-wild-type’ [6]. Due to the different AST methods used by the 
participants and to simplify interpretation of the results, throughout this report we will maintain the 
terms susceptible, intermediate and resistant also when we refer to wild-type and non-wild-type 
strains.  
Susceptibility results had to be interpreted on an individual basis for each antimicrobial tested 
according to the values listed in the protocol (App. 3). Participants were instructed to use the 
Salmonella / Shigella antisera and the antimicrobials used in the methods routinely performed. In 
addition, they were instructed to submit the breakpoints routinely applied in their laboratory for 
categorizing AST results, if different from those listed in the protocol. All laboratories were 
requested to enter MIC values for the C. jejuni (ATCC 33560) reference strain, and either zone 
diameters or MIC values for the E. coli (ATCC 25922) reference strain. After submitting the results, 
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participants were instructed to retrieve an instantly generated report from the secure web site. This 
report was created on an individual basis, and reported all deviations from the expected results and 
suggestions for solving or investigating the cause of error. Deviations of antimicrobial susceptibility 
test results from the expected results were categorized as minor, major or very major. Minor 
deviations are defined as classification of an intermediate strain as susceptible, resistant or vice 
versa (i.e. I ↔ S or I ↔R). Major deviation is the classification of a susceptible strain as resistant 
(i.e. S → R). Very major deviation is the classification of a resistant strain as susceptible (i.e. R → 
S). In this report, the deviations of AST results are divided into two categories, i.e. critical 
deviations which include major and very major deviations, and total deviations which include also 
the minor deviations.  
 
3. Results 
A total of 200 laboratories responded to the pre-notification and were enrolled in the EQAS. When 
the deadline for submitting results was reached, 192 laboratories in 93 countries had uploaded data. 
The following countries provided data for at least one of the EQAS components (Figure 1): 
Albania, Argentina, Australia, Barbados, Belarus, Belgium, Belize, Bolivia, Brazil, Brunei 
Darussalam, Bulgaria, Cambodia, Cameroon, Canada, Central African Republic, Chile, China, 
Colombia, Congo, Costa Rica, Côte d´Ivoire, Croatia, Cyprus, Czech Republic, Denmark, Ecuador, 
El Salvador, Estonia, Ethiopia, France, Germany, Greece, Grenada, Guatemala, Honduras, 
Hungary, India, Iran, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Korea, Lao, Lithuania, 
Luxembourg, Madagascar, Malawi, Malaysia, Malta, Mauritius, Mexico, Morocco, Nepal, New 
Zealand, Nicaragua, Nigeria, Oman, Palestine, Panama, Paraguay, Peru, Philippines, Poland, 
Russian Federation, Senegal, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, 
Sudan, Suriname, Sweden, Taiwan, Thailand, Trinidad and Tobago, Tunisia, Turkey, Ukraine, 
United Arab Emirates, United Kingdom, United States of America, Uruguay, Venezuela, Viet Nam, 
Zambia, and Zimbabwe. 
In contrast to 2011, the participation in the EQAS of 2012 increased by 26 institutes and three 
countries most likely due to the participation of Chinese laboratories in 2012. 
In the description of results, arbitrary thresholds of quality limits were not used. The results for AST 
are expressed as correct, minor, major, very major, and critical and total deviations as described 
above. 
A total of 190 laboratories received Salmonella strains, and 163 (86%) participated in the 
Salmonella serogrouping component of the EQAS, whereas 144 (76%) participated in the serotype 
module of the EQAS. In addition, 159 (84%) laboratories submitted AST results. Among the 
laboratories performing AST, 135 (85%) submitted results for the quality control (QC) strain E. coli 
ATCC 25922. The majority (98; 73%) of these laboratories used the disk diffusion method, while a 
MIC determination method was utilized by a smaller number (37; 27%) of laboratories. 
3.1 Methods used by EQAS participants 
Of 146 laboratories receiving Shigella strains, 128 (88%) submitted Shigella serogroup results 
(speciation) and 80 (55%) of these laboratories serogrouping the isolates further analyzed the strains 
to the serotype level. In addition, Shigella AST was performed by 120 (82%) of these laboratories. 
All participating laboratories were through the protocol given information regarding the breakpoints 
used for interpretation when generating the expected interpretation. Expected values were given as 
MIC-values only. In addition, all participating laboratories were instructed on interpretation of 
resistance to third generation cephalosporins and to fluoroquinolones.  
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Of the 135 laboratories receiving Campylobacter strains, all (135; 100%) reported identification 
results and 47 (35%) submitted AST results for both Campylobacter strains.  
Of the 147 laboratories receiving the unknown culture for identification, 134 (91%) submitted 
results. 
In 2012, the percentage of laboratories reporting complete serotype results for all eight strains 
decreased to 81% (n=122), a disruption of the increasing trend observed since 2008. However, the 
number of participants submitting results for all eight isolates increased by 13 participants in 2012 
compared to the previous year. Similarly, the proportion of correctly serotyped strains decreased 
from 92% (n=878) in 2011 to 83% (n=936) in 2012 despite an increase in participants submitting 
data (Table 1).  
3.2 Serogrouping and serotyping of Salmonella strains 
In Table 2, the number of participating laboratories is reported according to the number of correctly 
serotyped samples. In 2012, 68 (47%) of the 144 participating laboratories serotyped all eight 
strains correctly, and 29 (20%) laboratories correctly serotyped seven of the eight strains. In 
summary, in 2012, a total of 97 (67%) participating laboratories met the threshold for adequate 
performance of Salmonella serotyping, which represents a considerable decrease compared to 2011 
where 99 (81%) of the participating laboratories met the performance quality threshold. In addition, 
83% of the participating laboratories correctly identified half of the strains, which represents an 8% 
decrease compared to 2011 (91%). This is the poorest results for many years. Not since 2008 have 
we seen a similar poor result. In 2012, all participants again had at least one isolate correctly 
serotyped breaking the disruption of this trend from last year. 
In Table 3, the number of tested strains reported on a region-based categorization of participating 
laboratories was either the same or increased in all regions compared to 2011. In contrast, the 
performance of Salmonella serotyping was shockingly low for regions of developing countries 
compared with 2011. The accuracy of serotyping decreased with 19.2%, 39.1%, 25.0%, 10.6%, and 
20.6% in Africa, Central Asia & Middle East, Caribbean, Latin America, and Southeast Asia, 
respectively between 2011 and 2012. In Europe, North America, Oceania, and Russia, the decrease 
in accuracy of serotyping compared to 2011was lower than 4.5% and even close to 0% in Oceania 
and Russia.  
The overall performance of laboratories performing Salmonella serogrouping was moderate 
compared to 2011 where seven of the isolates had a deviation level below 5%. In 2012, several 
isolates seems to cause problems even in serogrouping where WHO S-12.2 (Liverpool; 
1,3,19:d:e,n,z15), WHO S-12.3 (Sundsvall; 6,14,25:z:e,n,x), and WHO S-12.8 (Hillingdon; 
9,46:g,m:-) resulted in the following percentage deviations; 25.3%, 16.0%, 29.4%, respectively 
(Table 4). 
Of 145 laboratories performing serotyping of the internal quality control strain (WHO S12.4, used 
in EQAS 2000, 2001, 2004, 2006 - 2011), 139 (96%) reported a correct result, thus leading to a 
deviation rate of 6% (Table 4). Thus in 2012, a slight decrease compared to 2011 in the ability of 
participating laboratories to correctly serotype the internal quality control strain was observed 
(Table 5).  
Deviations in Salmonella serotyping ranged from 4.1% (WHO S-12.4 internal quality control strain; 
S. Enteritidis) to 25.9% (WHO S-12.2 Liverpool; 1,3,19:d:e,n,z15) (Table 4). In 2012, all but the 
internal quality control strain exhibited deviation levels below the magic number of 10% deviations 
(Table 4).  
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A total of 13,042 antimicrobial susceptibility tests were performed in 2012 by 159 participating 
laboratories (Table 8). Of the submitted results, 94% were in agreement with the expected result, 
which is a slight increase compared to 2011 – and the best result ever only matched in 2009 (Table 
6). Minor, major and very major deviations were observed in 3%, 2% and 1% of the submitted 
results, respectively (Table 6). 
3.3 Antimicrobial susceptibility testing (AST) of Salmonella strains 
Some difficulties in assessing antimicrobial susceptibility were encountered for the tested 
combinations of strains and antimicrobials. The difficulties were mainly in assessing susceptibility 
to the usual antimicrobial suspects. This year, however, only to STR. Surprisingly, neither CIP, 
SMX, nor TET created problems (Table 7).  
Major deviations categorized by tested antimicrobial are reported in Table 8. Notably, a large 
number of total deviations were observed for CIP (11%). This antimicrobial together with STR 
resulted in high numbers of total deviations (Table 8).  
In 2012, the number of laboratories participating in the AST component of EQAS increased in all 
regions with exception of Russia (Table 9). The largest increased was observed in Central Asia & 
Middle East, Caribbean, Europe, Latin America and Southeast Asia. Overall, the performance of 
AST did not differ as much as in previous years ranging from 89.4% correct tests in among 18 
African countries to 97.4% in six Russian countries (Table 9).  
Antimicrobial susceptibility to E. coli ATCC 25922 was tested by 37 laboratories with the MIC 
determination method and by 98 laboratories with the disk diffusion method. The proportion of 
laboratories which submitted values outside the acceptable interval for the reference strain E. coli 
ATCC 25922 is reported in Table 10. The percentages of laboratories which reported MIC values 
outside the intervals accepted for the QC strain ranged from 0% (CHL, CRO, SXT, and TET) to 9% 
(TMP) (Table 10). These results indicate that there is no consistency with what caused problems in 
2011 – on the contrary. In 2011, 0% of laboratories reported MIC values for TMP outside the 
intervals accepted for the QC strain. In general, laboratories using the MIC determination method 
reported values within the acceptable interval in higher percentages compared to the laboratories 
using the disk diffusion method (Table 10).  
As in previous years, the performance of Shigella speciation was highly satisfactory in 2012, as the 
percentages of deviations were very low for all the four test strains, ranging from 0.8% (WHO SH-
12.2, WHO SH-12.3, and WHO SH-12.4) to 3.2% (WHO SH-12.1) (Table 11). The deviations 
observed among laboratories performing full serotyping were less satisfactory compared to 2011 
ranging from 3.6% (WHO SH-12.1) to 22.9% (WHO SH-12.4). The strain resulting in most 
deviations was WHO SH-12.4 – again this year; Shigella flexneri serotype 1b. The isolate was 
reported as serotype 1 (n=13), var. Y (n=2), 1a (n=1), 3 (n=1), 3b (n=1), and 6 (n=1) by the 
participating laboratories, respectively.  
3.4 Serogrouping and serotyping of Shigella strains 
In Table 12, the performance of Shigella serotyping is reported according to geographical 
distribution of participating laboratories. The number of participating laboratory increased in almost 
all regions compared to 2011 with exception of Russia. It was welcomed that one laboratory from 
Caribbean and eight from China this year participated. The accuracy of Shigella serotyping 
decreased considerable in all regions except for Southeast Asia where the performance increased 
from 84.8% in 2011 to 90.4% in 2012. 
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A total of 4,862 antimicrobial susceptibility tests were performed in 2012 by 120 participating 
laboratories. Agreement with the expected result was achieved in 91% of the reported results, which 
is consistent with previous years (Table 13). Minor, major and very major deviations were observed 
in 3%, 1% and 5% of reported results, respectively (Table 13). 
3.5 Antimicrobial susceptibility testing (AST) of Shigella strains 
Difficulties in assessing antimicrobial susceptibility to CHL, CIP, STR, SXT, and TET was 
encountered in isolate WHO SH-12.4 (Table 14). Overall, CHL, CIP, STR, and SXT accounted for 
11.5%, 38.6%, 27.1% and 8.1% of total deviations, respectively (Table 15).  
In 2012, all participating regions took part in the Shigella AST component. The majority of 
participating laboratories was located in the European, Latin American, Southeast Asian and 
African regions where 24, 23, 27 and 17 laboratories participated to this EQAS iteration, 
respectively (Table 16). By considering participating laboratories in relation to their geographical 
location, the percentage of correct AST results ranged from 82.6% (Africa) to 96.8% (Russia). The 
African, Caribbean, North American, and Southeast Asian regions reported results presenting the 
highest percentages of critical and total deviations, i.e. 13.2%, 14.6%, 10.5% and 7.6% critical 
deviations, and 14.7%, 16.0%, 10.5%, and 12.7% total deviations, respectively (Table 16). 
An optional part of the EQAS was to detect and confirm Extended-Spectrum Beta-Lactamase 
(ESBL) production. If participating in this item of the EQAS, all strains showing reduced 
susceptibility to cefotaxime (CTX), ceftazidime (CAZ) and/or ceftriaxone (CRO) should be tested 
for ESBL production. 
3.6 ESBL-producing Salmonella and Shigella 
None of the selected isolates were considered ESBL-producing. Uploaded results regarding ESBL-
producing strains are listed in Table 17 presenting the fact that almost all participating laboratories 
confirmed the isolates being non ESBLs. The deviating results observed were equivalent to only 
one laboratory (different from strain to strain) having uploaded incorrect results indicating an 
isolate being ESBL producer. 
Participation in the EQAS 2012 Campylobacter component was requested by 135 laboratories, of 
which all (135; 100%) submitted results within the deadline. Of the participating laboratories, 96% 
and 85% performed correct species identification for strain #1 (C. jejuni) and #2 (C. jejuni), 
respectively (Table 18). As expected, a considerable large number of laboratories reported the stains 
being C. coli. 
3.7 Identification of Campylobacter strains 
In Table 19, the performance of Campylobacter identification is reported according to geographical 
location of participating laboratories. A considering high number of participants from Central Asia 
& Middle East (going from 2 in 2011 to 11 in 2012) and Southeast Asia (going from 12 in 2011 to 
17 in 2012) were observed participating in the identification of Campylobacter strains. The 
accuracy in Campylobacter identification ranged from 57% (Caribbean) to 100% (Oceanic region). 
In 2012, the performance increased to levels similar to other years than 2011.  
A total of 419 MIC determinations were performed in 2012 by 47 participating laboratories (Table 
22). Among the reported results 93.6% were in agreement with the expected result (Table 20). 
Major and very major deviations were observed in 5.0% and 1.5% of reported results (Table 20). 
3.8 MIC determination of Campylobacter strains 
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None of the isolates seemed to created major difficulties in assessing antimicrobial susceptibility 
(Table 21). For the overall performance by antimicrobial, only STR seems to result in noteworthy 
deviations; 11.3% (Table 22).  
In 2012, MIC values were submitted by almost all laboratories with exception of Oceania and 
Russia (Table 23). An increase in participation was observed in many of the regions going up with 
one or two laboratories. However, in the Southeast Asian region the number of participating 
laboratories doubled in 2012 from five to ten laboratories. Agreement with expected values was 
observed in percentages ranging from 75.0% (Caribbean) to 100% (North America) (Table 23). The 
highest percentages of critical deviations were reported from laboratories in China, Caribbean, and 
Southeast Asian regions 11.5%, 25.0, and 14.2%, respectively (Table 23).  
MIC values of reference strain C. jejuni ATCC 33560 were tested by 34 laboratories. Of these, 21 
laboratories used micro-dilution procedures, while 13 laboratories used agar-dilution procedures 
and tested only CIP, ERY and GEN. Overall, the percentage of laboratories which submitted values 
within the acceptable interval for the reference strain seemed to experience most problems with CIP 
and ERY, which showed 81% and 80% results within range, respectively. (Table 24).  
Identification of the unknown enteric pathogen (Salmonella Paratyphi B var. Java) was performed 
by 134 laboratories (Table 25). Overall, 24% of the participating laboratories identified the strain as 
Salmonella Paratyphi B var. Java which require biochemical testing. 
3.9 Identification of the unknown culture 
 
4. Discussion 
After having conducted the GFN EQAS trials for more than ten years, we have actually covered the 
more common and frequent reported serovars. This makes it more challenging to find and include 
appropriate and interesting serovars in the trial panel to facilitate the global assessment of 
Salmonella serotyping capacity. This year, we chose serovars which have been reported in two GFN 
pilot surveillance studies conducted in Nigeria. The studies included serovars isolates from humans, 
poultry, poultry environment; litter, lizards etc., camels, cattle, pigs, fish, and vegetables providing 
an excellent insight of the epidemiology of Salmonella in Nigeria [7,8]. Many of the serovars 
observed in Nigeria are considered infrequent or rare in most other regions.  
4.1 Serogrouping and serotyping of Salmonella strains 
In the study by Raufu et al. [7], S. Eko was overall the second most prevalent serovar (17%) 
observed and isolated from cattle, camel, fish and human. In the same study, the serovar; S. 
Colindale was isolated from cattle (3.7%) and from humans (3.7%) and camels (11.8%) the serovar; 
S. Give was also observed [7]. Some of the same serovars were identified in another study focusing 
on Salmonella present in pig farms in Nigeria [8]. In the study, the authors observed that S. Give 
(15.7%), S. Colindale (6.6 %), and S. Hillingdon (5.7 %) were amongst the most predominant 
serovars in pig farming [8]. Similarly, another study from Gambia of invasive bacterial disease and 
association with mortality showed that the most common serovars in humans were S. Colindale 
(21.4%) indicating the importance of this serovar in this specific region [9]. The pig farming study 
also revealed some rarely described serovars such as S. Sundsvall S. Liverpool, and S. Wippra [8]. 
Those serovars are often related to lizards as described by Mascher et al. that also identified S. 
Wippra among household lizards in Nigeria [10]. Thus, lizards appear to play a major role in 
dissemination of the more rarely observed Salmonella serovars.  
 13 
Overall, the panel of 2012 was greatly influenced by rare or infrequently observed serovars from 
Nigeria but it also as in previous years include S. Enteritidis as it serves as internal control but also 
as it is one of the most frequent serovars worldwide despite a decreasing trend. 
The number of laboratories which serotyped all eight Salmonella strains decreased in 2012 to a 
2009 level. Similarly, also the percentage of correctly serotyped Salmonella strains decreased to a 
2008 level. However, it is still a satisfactory achievement to have 83% of the participants correctly 
serotype the Salmonella isolates and 122 participants attempting to serotype all eight Salmonella 
strains included the 2012 panel. This result might have been expected due to the higher number of 
participants in this year’s EQAS including the countries performing less well.  
The isolates included in this year’s EQAS was believed to be a bit more challenge to type compared 
to 2011 as we have four isolates containing both the E, G and L complexes which often is a 
challenge due to the many different antisera needed to pin out the correct antigens. Furthermore, 
three isolates were of a less common somatic antigen e.g. O:1,3,19, O:6,14,25, and O:9,46. 
Similarly, one isolate contained both the z6 and the z10
Almost 96% of participating laboratories correctly serotyped the internal control strain this year, 
which represent a minor decline in proficiency compared to previous years. This might also be 
related to the participation of more developing countries which most likely also profit from this 
participation in highlighting areas for improvement. The quality threshold of correctly serotyping at 
least seven strains was met by only 67% of participating laboratories, thus demonstrating once 
again the advanced level of required serotying capacity needed for this year’s EQAS. 
 H-antigen; all contributing to an advanced 
level of difficulty. 
In general, the obtained results indicate that most laboratories in the developing regions have less 
capacity to serotype the more challenging Salmonella serovars which potentially could be 
problematic if those become more frequent in the future.  
In 2012, the problems in serotyping the isolates are the same as in previous years. The problem is 
linked to difficulties in the characterization of flagellar antigens but this year also to some of the 
somatic antigens. In 2012, especially the complexes and somatic antigens related to “higher” 
serogroups played a significant role in the number of incorrect identification of the serotypes. This 
most likely is a consequence of a lack of good quality antisera, financial resources, and availability. 
However, we believe this problem will be diminished with time due to the advancing of new 
sequence-based molecular techniques and the decreasing price of those methods. In the future, we 
foresee that multi locus sequence typing (MLST) and whole genome sequencing will replace 
conventional microbiological techniques such as serotyping and identification of resistance genes, 
plasmids, virulence genes etc. [11, 12].  
Overall, 94% of the Salmonella AST was correctly performed with 3% of critical deviations. This 
result is the best ever reported matching the result of 2009 but with more laboratories participating. 
This might be the result of the strengthened awareness about antimicrobial resistance and the need 
for performing antimicrobial susceptibility testing accurately due to the emerging of multi-drug 
resistant (MDR) and extreme-drug resistant (XDR) bacterial pathogens worldwide. 
4.2 Antimicrobial susceptibility testing (AST) of Salmonella strains 
In 2012, we followed the guidelines for MIC breakpoint interpretation as well as the expert 
guidelines on the interpretation of cephalosporin resistance which was distributed in 2010. 
Similarly, participating laboratories were asked to utilize EUCAST epidemiologic cut off values for 
interpretation of CIP susceptibility. The EQAS organizers utilized the lower epidemiologic cut off 
value for ciprofloxacin to facilitate the detection of low-level resistance which may be caused either 
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by alteration of the drug target due to a single point mutation in the gyrase-encoding gene or by 
protection of the drug target due to qnr proteins which are encoded by plasmid-mediated genes. Of 
note, low-level ciprofloxacin-resistant strains (extra-intestinal non-typhoid Salmonella and S. 
Typhi) would be interpreted as intermediate according to the CLSI clinical breakpoints available 
(M100-S22). However, this will not determine plain non-typhoid Salmonella or extra-intestinal 
non-typhoid Salmonella and S. Typhi as resistant toward fluoroquinolones even by using the CLSI 
guidelines of 2012 why we maintain the EUCAST guidelines for interpretation of these compounds. 
In 2011, CIP and NAL seemed to cause some challenges which were linked to detection of qnr 
genes in some of the isolates where participants indicated those isolates incorrectly as intermediate 
or resistant for NAL and the opposite for CIP. In 2012, none of the panel isolates harboured qnr 
genes and only one isolates were resistant to both CIP and NAL why the interpretation was quite 
easy resulting in few mistakes for these compounds. 
As in previous years, a high percentage of total deviations were observed for CIP and, STR 
susceptibility tests. Interestingly, TET and SMX susceptibility tests seemed not to create that many 
deviations in 2012 compared to previous years. In the case of STR susceptibility test, the difficulties 
in testing this compound appear to be continuous. In Europe, discussions have been raised about the 
value of keeping this drug in the panel of antimicrobials ideal for monitoring. Publications 
suggesting new and updated cut off values for STR have also shown an overlapping distribution 
between the wild-type and non-wild-type complicating the exact determination of the resistant 
population [13].  
In the case of SMX susceptibility test, we observed a decrease in deviating results since 2010. A pit 
fall as regards reading the result of this antimicrobial is caused by the fact that it is bacteriostatic, 
meaning that the zone diameter or the MIC should be read at 80% reduction of growth. A common 
mistake for this antimicrobial is therefore to register false resistance. This year, two of the test 
strains were resistant to SMX which might explain the decrease in deviating results. 
In general, data from the Salmonella AST component of EQAS 2012 demonstrate an excellent 
performance compared to previous years. Of note, all laboratories with exception of Caribbean 
performed better compared to 2011.  
When performing AST, the inclusion of reference strains for internal QC is extremely important. If 
correctly used, the reference strain will provide QC for both the method and the reagents. 
Unfortunately, only 135 (85%) participating laboratories submitted AST results of the QC strain. 
Thus a poor result compared to 2011. We always encourage laboratories to conduct quality 
assurance when performing AST. To facilitate the internal QC, we provide each new participating 
laboratory with the reference strain E. coli ATCC 25922. Laboratories participating in EQAS are 
invited to retain and maintain the QC strain for future use. As a rule, results for the test organisms 
should not be reported if ≥ 3 out of 30 results for the QC strain are outside the expected interval. In 
2012, we again observed an improvement in AST of QC strains using MIC determination compared 
to 2010. Compared to disk diffusion, similar or worse results were obtained in 2012 as to data 
outside the QC ranges. These erroneous disk diffusion results typically arise from inadequate 
standardization of methodologies, lack of good quality culture media and improper storage of 
antimicrobial-containing disks. Thus, deviations in AST results can likely be corrected by 
improving QC practices.  
In EQAS 2012, 122 to 128 correctly identified the four Shigella isolates resulting in a deviation 
range of 0.0% to 3.2% showing a high capacity within Shigella diagnostics.  
4.3 Serogrouping and serotyping of Shigella strains 
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The performance in the serotyping the four Shigella isolates were considerable lower compared to 
conducting correct identification. In 2012, three of the four isolates caused most deviations in 
serotyping ranging from 12.8% to 22.9%. A total of 19 laboratories failed to detect the right 
serotype related to serovar 1b in S. flexneri.  
All regions except for Southeast Asia and Oceanic encountered a drop in serotyping performance 
but an overall increase in participation. Thus indicating the same hypothesis as for the Salmonella 
component that the increase of developing countries in 2012 might be the result of the less 
satisfactory results due to lack of appropriate high quality antisera. There needs to be a discussion in 
WHO how to facilitate the needed antisera. 
In EQAS 2012, AST of Shigella spp. was performed by 120 laboratories which is the top 
participation in this component since its inclusion in 2008. A total of 91% of the participants 
obtained a correct AST results which is within the same level previous years (91%-96%) and as for 
AST in Salmonella. In comparison with the Salmonella results, a few more deviations categorized 
as very major deviations were observed. Overall, the AST results of the Shigella component were 
equal to what was seen in 2010 and 2011.  
4.4 Antimicrobial susceptibility testing (AST) of Shigella strains 
The results show that especially isolate WHO SH-12.4 caused some problems susceptibility testing 
towards CHL, CIP, STR and SXT. In general, a large proportion of deviations testing CHL and CIP 
were observed associated with isolates WHO SH-12.2 to WHO SH-12.4. None of the isolates were 
ESBL producers. 
The high number of deviations to CIP was most likely related to the reduced susceptibility due to 
only one point mutation in the gyrase gene and the lack of CLSI breakpoints. The problems related 
to SXT and STR have previously been discussed for Salmonella where SXT is related to the disk 
diffusion reading difficulties and STR to breakpoints.  
All regions submitted results with an overall regional performance similar to the one described for 
Salmonella AST differing with a maximum of 5%.  
In 2012, we selected only Campylobacter jejuni strains. Interestingly, the results from this EQAS 
support the hypothesis raised in 2011 that correct identification of C. jejuni seems to be easier than 
that of C. coli as 85% and 96% of the participating laboratories obtained a correct identification for 
the two C. jejuni isolates. One of the explanations may be that when conducting a conventional 
hippurate hydrolysis test, that some C. coli are incorrectly identified based on false positive 
hippurate hydrolysis test results. The weakness of the conventional hippurate hydrolysis test is that 
sometimes the test suspensions develop a weak bluish color when testing C. coli that for the 
untrained person often will be mistaken as being positive indicating C. jejuni. In contrast, testing C. 
jejuni will provide a strong blue coloration of the suspensions which is easy to interpret. We noticed 
in 2012, a considerable increase in participation from Central Asia & Middle East and Southeast 
Asia as in some of the other components. Overall, the results related to Campylobacter 
identification were quite satisfactory in all regions in 2012.  
4.5 Identification of Campylobacter strains  
In EQAS 2012, 47 laboratories participated in the MIC determination and performed overall 
satisfactorily, since they obtained 93.6% correct test results. In contrast to 2011, only minor 
problems testing the antimicrobials were observed with most deviations observed to STR. In 2012, 
no laboratories from Russia and Oceanic region participated. However, in some regions the 
4.7 Antimicrobial susceptibility testing (AST) of Campylobacter strains 
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participation increased considerably, e.g. for Southeast Asia with five laboratories in 2011 to ten in 
2012.  
In 2012, 34 (72%) participating laboratories submitted AST results for the QC strain. The majority 
of deviations were observed for susceptibility testing by micro-dilution at 42 °C. Interestingly, we 
noticed the same deviations in previous years. Some problems were observed towards testing CIP. 
In general, AST of the QC strain was satisfactory.  
In EQAS 2012, we included a Salmonella Paratyphi B var. Java strain to see how many of the 
participating laboratories that would be able to correctly distinguish between the Foodborne 
pathogen; Salmonella Paratyphi B var. Java and the person to person transmitted a Salmonella 
Paratyphi B. This is important to distinguish between the two as the epidemiology and prevention/ 
control is completely different. Serotyping would be the first step toward the identification but 
cannot in this case stand alone. Correct identification of this organism also requires tartrate testing 
to differentiate between the two the biovars. This is the reason why only the following test results 
are acceptable; Salmonella spp., Salmonella Group B, Salmonella Paratyphi B var. Java, Salmonella 
Paratyphi B var. L (+) tartrate +. In contrast, Salmonella Paratyphi B; since this is unspecific and 
must be further defined as the given variant to be correct is treated as incorrect. 
4.8 Identification of the unknown culture 
Of 134 laboratories delivering results, 54% identified the strain correctly; 24%, 23%, 7% as 
Salmonella Paratyphi B var. Java, Salmonella spp., and Salmonella Group B, respectively. This 
indicates that half of the laboratories in fact do not differentiate between the two the biovars despite 
them being quite difference in the epidemiology. 
 
5. Conclusions  
The acceptance threshold for the Salmonella serotyping EQAS component was met by 67% (n=97) 
of the participating laboratories. In addition, 81% of the laboratories tested all eight strains and a 
total of 83% of all tests were correct, thus representing a decrease compared to 2011. Similarly, the 
ability in correctly testing the internal QC strain decreased from 97% in 2011 to 96% this year.  
This year, the obtained results indicate that laboratories in the developing part of the world have 
lower capacity to serotype the rarer and more infrequent Salmonella serovars requiring more 
advanced sets of antisera. It is noteworthy to mention that more countries from the developing 
regions participated in this component of the EQAS compared to 2011. 
The main problem as regards serotyping appears to have been linked to difficulties in the 
characterization of both the somatic and flagellar antigens. In 2012, this especially concerns the 
complexes E, L and G and somatic antigens of higher serogroups which is most likely a 
consequence of a lack of good quality antisera, financial resources, and availability. In the future, 
however, it is likely that sequence-based molecular techniques will be competitive with traditional 
typing methods. 
Concerning the Salmonella AST component, the EQAS 2012 results as regards AST of Salmonella 
showed slight increase compared to 2011 – and the best result ever only matched in 2009. Overall, 
the acceptance threshold was met, and we identified 3% minor, 2% major and 1% very major 
deviations. STR was the only antimicrobial that caused the difficulties of the observed deviations. 
Compared to 2011, the performance of AST did not differ as much between the different regions.  
Strengthened awareness of the importance of performing internal quality control is crucial and is 
introduced in many of the participating laboratories. Twenty-four (15%) participating laboratories 
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did not report data for AST of the QC strain, though, despite the EQAS organizers’ repeated 
recommendation of the use of such QC strains and the provision of certified strains to new 
participants. It is important to emphasize that this component represents the true indicator of the 
quality of AST performance.  
For the Shigella component in EQAS 2012, consisting of serogrouping, serotyping and AST, most 
laboratories correctly serogrouped the four Shigella strains, and a maximum of 3.2% deviations was 
observed. A total of 80 laboratories performed serotyping. The number of participating laboratory 
increased in almost all regions compared to 2011 with exception of Russia. It was welcomed that 
one laboratory from Caribbean and eight from China participated this year. 
The results obtained in the Shigella AST were in 91% of the cases in agreement with the expected 
result which is consistent with previous years. 
A total of 135 laboratories received Campylobacter for identification, and all of these laboratories 
uploaded data. Both strains were C. jejuni and resulted in 96% and 85% correct species 
identification, respectively. The accuracy in Campylobacter identification ranged from 57% 
(Caribbean) to 100% (Oceanic region). In 2012, the performance increased to levels similar to other 
years than 2011.  
EQAS 2012, a total of 34 laboratories participated in MIC determination of Campylobacter. The 
acceptance threshold used for Salmonella was applied and was almost met, since we observed 6.5% 
critical deviations. For the overall performance by antimicrobial, only STR seems to result in 
noteworthy deviations; 11.3%. Overall, the percentage of laboratories which submitted values 
within the acceptable interval for the reference strain seemed to experience most problems with CIP 
and ERY, which showed 81% and 80% results within range, respectively.  
The unknown strain; Salmonella Paratyphi B var. Java, was selected to see how effectively the 
participants could distinguish between the Foodborne pathogen; Salmonella Paratyphi B var. Java 
and the person to person transmitted Salmonella Paratyphi B. Of 134 laboratories delivering results, 
54% identified the strain correctly; 24%, 23%, 7% as Salmonella Paratyphi B var. Java, Salmonella 
spp., and Salmonella Group B, respectively. This indicates that half of the laboratories in fact do not 
differentiate between the two the biovars despite them being quite difference in the epidemiology.  
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Figure and Tables 
 
Figure 1. Countries participating* in the WHO EQAS 2012 
 
 
*marked in green.  
 2 
Table 1. EQAS participating laboratories’ performance of Salmonella serotyping  
 
EQAS 
iteration 
 
Labs serotyping all 
provided strains Correct test results 
No. % No. % 
2000 34 92 165 76 
2001 79 82 513 72 
2002 80 81 668 91 
2003 69 54 692 80 
2004 78 61 701 81 
2006 105 81 808 85 
2007 109 78 920 88 
2008 100 66 888 83 
2009 119 83 974 86 
2010 129 87 998 89 
2011 109 89 878 92 
2012 122 81 936 83 
Average 94 79 762 85 
 
Table 2. Ability of EQAS participating laboratories to serotype the test Salmonella strains  
 
Number 
of strains 
correctly 
serotyped 
Participating laboratories 
EQAS 
2000 
EQAS 
2001 
EQAS 
2002 
EQAS 
2003 
EQAS 
2004 
EQAS 
2006 
 
No. % No. % No. % No. % No. % No. % 
8 9 24 34 35 52 53 32 25 41 32 42 32 
7 9 24 13 14 19 19 15 12 14 11 35 27 
6 4 11 9 9 12 12 18 14 16 13 19 15 
5 3 8 9 9 4 4 23 18 16 13 12 9 
4 3 8 4 4 1 1 14 11 11 9 7 5 
3 4 11 8 8 4 4 13 10 10 8 5 4 
2 2 5 3 3 5 5 4 3 10 8 3 2 
1 2 5 5 5 1 1 5 4 5 4 4 3 
0 1 3 11 11 1 1 3 2 4 3 3 2 
In total 37 100 96 100 99 100 127 100 127 100 130 100 
Number 
of strains 
correctly 
serotyped 
Participating laboratories 
EQAS 
2007 
EQAS 
2008 
EQAS 
2009 
EQAS 
2010 
EQAS 
2011 
EQAS 
2012 
AVERAGE 
EQAS 
2000 - 2012 
No. % No. % No. % No. % No. % No. % No. % 
8 66 47 50 33 76 50 91 61 82 67 68 47 643 44 
7 29 21 36 24 29 19 16 11 17 14 29 20 261 18 
6 13 9 11 7 7 5 12 8 10 8 14 10 145 10 
5 11 8 14 9 13 8 9 6 2 2 9 6 125 8 
4 7 5 12 8 5 3 6 5 4 3 5 3 79 5 
3 6 4 9 6 7 5 2 1 4 3 6 4 78 5 
2 2 1 8 6 5 3 2 1 1 1 10 7 55 4 
1 6 4 9 6 6 4 7 5 3 2 2 1 55 4 
0 0 0 2 1 5 3 3 2 0 0 1 1 34 2 
In total 140 100 151 100 153 100 148 100 123 100 144 100 1475 100 
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Table 3. Region-based categorization of EQAS participants’ performance of Salmonella serotyping 
 
Region EQAS iteration 
No. of 
labs 
No. of 
strains 
serotyped  
% strains 
correctly 
serotyped 
Countries participating 
in EQAS 2012 
Africa 
2001 6 37 73.0 
Cameroon, Central African 
Republic, Congo, Rep. of, Ivory 
Coast, Madagascar, Mauritius, 
Morocco, South Africa,  
Tunisia, Zimbabwe 
2002 9 62 87.1 
2003 11 70 71.4 
2004 9 51 62.7 
2006 16 95 71.6 
2007 11 73 80.8 
2008 10 71 49.3 
2009 15 94 75.5 
2010 13 83 67.5 
2011 10 57 79.2 
2012 10 65 60.0 
Central Asia & 
Middle East  
2001 10 60 50.0 
Israel, Jordan, Oman,  
Palestine 
 
2002 5 30 83.3 
2003 5 35 54.3 
2004 5 33 54.5 
2006 5 35 74.3 
2007 5 40 55.0 
2008 5 34 61.8 
2009 5 32 46.9 
2010 5 22 75.9 
2011 3 23 95.8 
2012 4 30 56.7 
      
Caribbean 
2001 0 0 0 
Barbados,  
Trinidad and Tobago 
 
2002 0 0 0 
2003 3 18 61.1 
2004 2 8 87.5 
2006 3 14 78.6 
2007 2 9 77.8 
2008 3 14 78.6 
2009 3 12 83.3 
2010 2 13 92.9 
2011 1 7 87.5 
2012 2 16 62.5 
Europe  
2001 43 323 80.5 
Albania, Belgium, Bulgaria (2), 
Croatia, Cyprus, Czech Republic, 
Denmark (2), Estonia, France, 
Germany, Greece (3), Hungary, 
Ireland, Italy (15),  
Lithuania, Luxembourg, Malta, 
Poland (3), Serbia, Slovakia (2), 
Slovenia, Spain, Sweden,  
Turkey (2), United Kingdom 
2002 50 384 90.0 
2003 60 401 84.8 
2004 57 392 84.7 
2006 52 403 86.4 
2007 54 415 89.4 
2008 50 379 82.3 
2009 47 362 93.1 
2010 45 332 94.1 
2011 42 314 94.6 
2012 47 368 92.9 
 
 4 
Table 3 (continued).  
Region-based categorization of EQAS participants’ performance of Salmonella serotyping 
 
Region EQAS iteration 
No. of 
labs 
No. of 
strains 
serotyped  
% strains 
correctly 
serotyped 
Countries participating 
 in EQAS 2012 
North America  
2001 4 32 87.5 
Canada (10), United States of 
America (4) 
2002 2 16 100.0 
2003 6 41 95.1 
2004 8 55 81.8 
2006 10 80 96.3 
2007 12 94 97.9 
2008 11 84 95.2 
2009 12 90 92.2 
2010 13 103 100.0 
2011 11 81 97.6 
2012 14 101 93.1 
      
Oceania  
2001 4 30 100.0 
Australia (3), New Zealand 
2002 6 43 93.0 
2003 6 46 93.5 
2004 5 38 97.4 
2006 5 37 94.6 
2007 4 32 100.0 
2008 4 30 93.3 
2009 4 32 96.9 
2010 4 32 100.0 
2011 4 32 100.0 
2012 4 32 100.0 
Russia  
2001 1 8 12.5 
Belarus, Georgia, Russia (4) 
2002 1 8 62.5 
2003 1 7 14.3 
2004 4 26 69.2 
2006 5 40 80.0 
2007 8 51 80.4 
2008 6 40 90.0 
2009 7 49 91.8 
2010 8 54 87.1 
2011 7 48 87.3 
2012 6 48 87.5 
      
Latin America  
2001 11 78 57.7 
Argentina (2), Bolivia, Brazil (2), 
Chile (2), Colombia (3),  
Costa Rica (2), Ecuador (2), 
Grenada, Honduras, Mexico, 
Nicaragua, Panama (2), Paraguay, 
Peru (2), Uruguay, Venezuela 
2002 11 82 87.8 
2003 13 83 75.9 
2004 15 88 79.5 
2006 13 84 84.5 
2007 15 107 88.8 
2008 17 120 71.7 
2009 21 150 77.3 
2010 22 132 80.0 
2011 23 144 83.7 
2012 25 182 73.1 
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Table 3 (continued).  
Region-based categorization of EQAS participants’ performance of Salmonella serotyping 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Region EQAS iteration 
No. of 
labs 
No. of 
strains 
serotyped  
% strains 
correctly 
serotyped 
Countries participating 
 in EQAS 2012 
Southeast Asia  
2001 15 113 54.0 
Brunei Darussalam, Cambodia,  
India (2), Japan (2),  
Korea Rep. of (2),  
Lao P.´s Dem. Rep., Malaysia (4),  
Philippines, Singapore,  
Taiwan, Thailand (10), Viet Nam. 
 
2002 12 90 92.2 
2003 15 100 81.0 
2004 17 130 81.5 
2006 15 117 84.6 
2007 19 140 91.4 
2008 18 125 81.6 
2009 23 180 81.1 
2010 24 172 90.5 
2011 23 180 98.4 
2012 28 207 77,8 
      
China  
2001 4 32 96.9 
China 
2002 3 24 100.0 
2003 8 60 75.0 
2004 7 46 78.3 
2006 6 48 85.4 
2007 10 80 91.3 
2008 15 108 94.4 
2009 16 126 95.2 
2010 10 74 92.5 
2012 10 78 80,8 
 6 
Table 4. Salmonella serogroups (SG), serotypes (ST) and deviations (D), WHO EQAS 2012 
 
*number of participants reporting the specified deviating result 
 
  
Strain 
ID Correct serotype 
No. of 
labs 
reportin
  
% DSG 
No. of labs 
reporting 
ST 
% 
DST 
Deviating results (*) 
WHO 
S-12.1 Wippra 6,8:z10:z6 159 3.8 142 16.9 
Molade (8), Hadar (2), Mapo (2),  
Zerifin (2), Banalia, Curacao, Kentucky, 
Labadi, Lindemburg, Muenchen, Redba, 
Remiremont, Paratyphi C, Tado. 
WHO 
S-12.2 Liverpool 1,3,19:d:e,n,z15 158 25.3 143 25.9 
Madjorio (15), Souza (3), Umbadah (2), 
Sao (2), Anatum, Avonmouth, Bethune, 
Bilu, Bolton, Cannonhill, Everleigh, II 
3,10:e,n,x:1,7, Machaga, Nitra, Paratyphi 
A, Shangani var. 15+, Typhi, 
Typhimurium, Yalding. 
WHO 
S-12.3 Sundsvall 6,14,25:z:e,n,x 150 16.0 133 24.1 
Soahanina (9), Cayar (3), Kastrup (3),  
Royan (2), Amersfoort var. 14+, Bessi, 
Bousso, Breukelen, Caracas, Homosassa,  
Kalumburn, Larochelle, Madelia, Poana,  
Poano, Paratyphi C, Schoeneberg, Typhi, 
Virchow. 
WHO 
S-12.4 Enteritidis 9,12:g,m:- 163 3.1 145 4.1 
Caracas, Essen, Groupe II, Gueuletapee, 
Typhi, Salmonella 
WHO 
S-12.5 Eko 4,12:e,h:1,6 162 0.6 143 14.0 
Reading (5), Chester (3), Saintpaul (3), 
Sandiego (2), Agama, Chartres, 
Enteritidis, II .4,12;e,n,x;1,2,7, Kaapstad,  
Paratyphi B, Typhimurium 
WHO 
S-12.6 Colindale 6,7:r:1,7 159 2.5 142 13.4 
Virchow (8), Nigeria (3), Infantis (2), 
Give, Grampian, Huddinge, Lika, Lomita, 
Paratyphi C. 
WHO 
S-12.7 Give 3,10:l,v:1,7 153 5.9 136 14.0 
London (6), Nchanga (2), Amager, 
Concord, Fann, Groupe II, Gueuletapee, 
Mendoza, Ngor, Nitra, Parkroyal, Ruzizi, 
Sinstorf 
WHO 
S-12.8 Hillingdon 9,46:g,m:- 160 29.4 143 23.8 
Enteritidis (29), Blegdam, Gueuletapee, 
Nchanga, Sangalkam, Suberu 
 7 
Table 5. EQAS participating laboratories’ performance of internal quality control strain (WHO  
S-12.4, Salmonella Enteritidis) serotyping  
 
EQAS 
iteration 
Labs serotyping  
S. Enteritidis correctly 
No. % 
2000 34 92 
2001 64 84 
2004 113 95 
2006 116 94 
2007 135 96 
2008 139 96 
2009 141 93 
2010 138 97 
2011 128 98 
2012 139 96 
Average 115 95 
 
 
 
Table 6. EQAS participating laboratories’ performance of antimicrobial susceptibility testing of Salmonella strains 
 
EQAS 
iteration 
No. of EQAS 
participating 
laboratories  
% correct test 
results 
 
% minor deviations 
(S ↔ I or I ↔ R)^  
% major 
deviations 
(S → R)^ 
% very major 
deviations  
(R→ S)^ 
% critical deviations 
(R→ S & S → R)^ 
% total deviations 
(S → R & R → S & S ↔ 
I or I ↔ R)^ 
2000 44 92 4 4 0 4 8 
2001 108 91 6 2 1 3 9 
2002 119 92 6 2 1 3 9 
2003* 147 93 4 3 0 3 7 
2004 152 93 4 2 1 3 7 
2006 143 88 8 3 1 4 12 
2007 143 93 4 2 1 3 7 
2008 168 91 4 2 3 5 9 
2009 153 94 3 2 1 3 6 
2010 152 92 4 3 2 5 8 
2011 127 91 4 2 3 5 9 
2012 159 94 3 2 1 3 6 
Average* 135 92 5 2 1 4 8 
*Data do not include one strain which may have lost resistance due to transport or storage stress 
^S, susceptible; I, intermediate; R, resistant 
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Table 7. Antimicrobial susceptibility test results (number of R/I/S) for the EQAS 2012 Salmonella strains* 
 
^For antimicrobial abbreviations: see List of Abbreviations page 1 
*In bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation. R, resistant/I, intermediate/ S, susceptible. 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Antimicrobial^ 
AMP CTX CAZ CRO CHL CIP GEN NAL STR SMX SXT TET TMP 
WHO 
S-12.1 3/0/151 6/2/125 1/3/121 2/0/103 0/0/146 3/1/152 5/1/139 3/2/135 9/40/53 8/2/62 2/0/131 0/4/143 1/0/76 
WHO 
S-12.2 5/2/146 4/1/127 2/0/121 3/2/98 1/0/143 7/1/147 5/1/139 1/2/139 3/29/69 4/1/68 4/1/125 2/4/139 1/0/75 
WHO 
S-12.3 6/0/146 3/1/128 2/0/122 3/0/102 1/1/142 11/1/144 5/1/139 3/7/132 2/8/91 9/0/64 4/0/127 2/3/140 2/0/74 
WHO 
S-12.4 4/17/132 10/2/120 5/1/119 4/0/100 0/4/141 14/1/141 139/2/4 2/2/140 93/8/4 72/0/1 1/1/130 8/10/129 1/0/76 
WHO 
S-12.5 148/1/4 3/1/128 3/0/121 3/0/100 1/1/143 4/0/152 5/1/138 1/3/139 4/22/74 71/1/0 128/1/2 139/1/4 76/0/0 
WHO 
S-12.6 4/1/149 4/1/127 2/1/120 2/0/103 2/0/143 7/0/148 4/2/139 1/3/137 3/23/75 5/2/65 1/0/132 2/3/139 1/1/74 
WHO 
S-12.7 4/4/146 3/1/128 1/0/123 1/0/103 138/1/5 64/8/83 5/1/140 137/0/6 2/17/84 2/0/73 1/0/130 139/1/5 1/0/77 
WHO 
S-12.8 4/1/150 7/2/124 2/0/123 2/1/102 2/2/142 11/1/144 5/0/141 4/5/132 18/41/42 3/3/68 0/2/131 2/3/141 1/0/76 
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Table 8. EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP POD CRO CTX GEN KAN NAL SMX STR SXT TET TMP XNL OVERALL 
2000 44 
No. of tests - 343 - 343 334 -     343 312 328 248 312 - 335 295 - 3,193 
% critical deviations* - 6 - 4 1 -     4 4 1 3 4 - 6 1 - 3 
% total deviations^ - 8 - 7 6 -     5 16 4 5 12 - 13 1 - 8 
2001 108 
No. of tests - 822 - 814 813 -     821 623 726 431 679 757 804 416 - 7,706 
% critical deviations*  - 4 - 2 1 -     2 2 2 6 7 2 7 1 - 3 
% total deviations^ - 7 - 3 4 -     4 7 8 9 27 5 18 2 - 9 
2002 119 
No. of tests - 918 - 903 911 -     905 680 885 495 718 724 861 499 - 8,499 
% critical deviations* - 2 - 2 0 -     2 2 2 4 4 7 3 3 - 3 
% total deviations^ - 3 - 3 2 -     16 10 4 4 34 10 7 3 - 9 
2003● 147 
No. of tests - 1,019 - 996 995 -     993 738 947 615 768 929 995 582 - 9,577 
% critical deviations* - 2 - 1 0 -     2 2 1 4 9 2 4 1 - 3 
% total deviations^ - 4 - 2 1 -     2 6 4 5 39 2 11 1 - 7 
2004 152 
No. of tests 973 1,178 - 1,159 1,162 - - 995 1,201 - 1,130 734 947 1051 1,122 729 - 12,381 
% critical deviations* 6 3 - 2 0 - - 0 2 - 1 5 1 3 5 2 - 3 
% total deviations^ 12 5 - 2 1 - - 14 3 - 4 8 21 4 11 2 - 7 
2006 143 
No. of tests 950 1,092 769 1,060 1,110 305 - 956 1,078 - 1,035 649 896 996 1,054 607 225 12,782 
% critical deviations* 9 2 7 3 2 1 - 7 3 - 2 6 5 3 9 1 2 4 
% total deviations^ 22 3 11 15 6 26 - 15 7 - 6 7 22 5 20 2 9 12 
2007 143 
No. of tests 908 1,114 830 1,105 1,101 389 - 914 1,111 - 1,092 678 875 971 1,047 583 258 12,976 
% critical deviations* 6 5 1 0 1 4 - 1 3 - 2 5 4 3 4 1 0 3 
% total deviations^ 17 7 1 6 1 16 - 2 4 - 3 6 26 3 11 2 6 7 
2008 168 
No. of tests - 1,331 961 1,226 1,307 - 791 1,104 1,265 - 1,168 718 867 1,155 1,249 696 - 13,858 
% critical deviations* - 3 3 1 19 - 3 3 4 - 2 4 7 3 6 2 - 5 
% total deviations^ - 8 6 11 21 - 6 6 6 - 4 5 25 4 13 2 - 9 
2009 153 
No. of tests - 1,206 921 1,108 1,190 - 775 1,009 1,143 - 1,095 624 864 1,042 1,114 616 - 12,707 
% critical deviations* - 3 1 1 8 - 0 1 2 - 1 7 9 3 4 1 - 3 
% total deviations^ - 6 1 2 10 - 1 2 3 - 3 9 30 4 10 1 - 6 
2010 152 
No. of tests - 1,173 937 1,118 1,194 - 787 1,026 1,133 - 1,096 566 800 1,012 1,134 604 - 12,580 
% critical deviations* - 4 2 1 3 - 4 4 5 - 1 14 19 4 5 1 - 5 
% total deviations^ - 5 3 2 3 - 8 8 6 - 2 17 55 4 9 1 - 9 
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Table 8 (continued). EQAS participants’ performance of Salmonella strains antimicrobial susceptibility testing categorized by antimicrobial. 
 
Legend Figure 8 
 
∞
*R→ S & S → R (R, resistant; S, susceptible) 
For antimicrobial abbreviations: see List of Abbreviations page 1 
^S→R & R→S & S↔I or I↔R (I, intermediate) 
●
-, not determined 
 Data do not include one strain which may have lost resistance due to transport or storage stress 
 
 
EQAS 
iteration 
No. of 
labs Performance 
Antimicrobial∞ 
AMC AMP CAZ CHL CIP POD CRO CTX GEN KAN NAL SMX STR SXT TET TMP XNL OVERALL 
2011 127 
No. of tests - 1099 829 988 1070 - 744 909 999 - 993 542 682 988 1017 493 - 11,353 
% critical deviations* - 5 3 2 20 - 3 4 4 - 7 4 3 3 4 1 - 5 
% total deviations^ - 6 4 2 21 - 3 6 5 - 15 5 42 3 10 2 - 9 
2012 159 
No. of tests - 1228 993 1159 1245 - 834 1058 1161 - 1136 584 814 1054 1163 613 - 13,042 
% critical deviations* - 3 2 1 11 - 2 4 3 - 2 5 2 1 2 1 - 3 
% total deviations^ - 5 2 2 12 - 3 5 4 - 4 7 35 2 5 1 - 7 
Average● 135 
No. of tests 236 368 520 434 448 58 328 403 436 196 418 574 769 623 432 561 40 2,042 
% critical deviations* 2 4 2 2 6 0 1 2 3 1 2 6 6 3 5 1 0 4 
% total deviations^ 4 6 2 5 7 4 2 5 5 3 5 7 31 4 12 2 1 8 
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Table 9. Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial susceptibility testing 
 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test 
result 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2012 iteration 
A
fr
ic
a 
2001 7 80.1 9.6 7.7 2.5 10.2 19.8 
Cameroon, Central 
African, Republic 
Congo, Rep. of, Ivory 
Coast, Ethiopia, Kenya, 
Madagascar, Malawi, 
Mauritius, Morocco (2), 
Nigeria (2), Senegal, 
South Africa, Sudan, 
Tunisia, Zambia, 
Zimbabwe 
2002 10 94.3 4.1 1.0 0.6 1.6 5.7 
2003 13 86.9 6.6 2.8 3.7 6.5 13.1 
2004 11 85.7 7.2 5.2 1.9 7.1 14.3 
2006 20 85.8 7.5 4.1 2.7 6.8 14.3 
2007 16 90.7 4.4 4.0 0.9 4.9 9.3 
2008 19 83.8 6.5 5.5 4.2 9.7 16.2 
2009 22 90.1 4.5 3.6 1.8 5.4 9.9 
2010 22 84.7 6.0 6.5 2.8 9.3 15.3 
2011 17 87.0 5.0 4.7 3.3 8.0 13.0 
2012 18 89.4 5.3 3.5 1.9 5.4 10.6 
C
en
tr
al
 A
sia
 &
 M
id
dl
e 
Ea
st
  2001 10 87.7 6.3 5.2 0.8 6.0 12.3 
Iran Islamic Rep of (2), 
Israel, Jordan, 
Oman (2), Palestine,  
United Arab Emirates 
 
 
2002 6 83.4 9.8 6.6 0.2 6.8 16.6 
2003 8 89.9 4.5 4.0 1.6 5.6 10.1 
2004 10 87.5 6.7 5.5 0.3 5.8 12.5 
2006 7 79.2 10.5 9.8 0.5 10.3 20.8 
2007 8 87.8 5.0 6.2 1.1 7.3 12.2 
2008 12 86.1 6.5 4.0 3.4 7.4 13.9 
2009 6 93.7 4.3 0.9 1.1 2.0 6.3 
2010 7 95.8 2.6 0.2 1.4 1.6 4.2 
2011 4 91.8 4.1 1.8 2.3 4.1 8.2 
2012 8 92.8 4.4 1.6 0.7 2.3 6.6 
C
ar
ib
be
an
  
2001 2 83.5 9.5 7.0 0.0 7.0 16.5 
Barbados, Jamaica (2), 
Trinidad and Tobago  
 
2002 1 95.8 4.2 0.0 0.0 0.0 4.2 
2003 8 91.7 6.4 1.5 0.5 2.0 8.4 
2004 8 94.1 3.1 1.9 0.9 2.8 5.9 
2006 5 92.1 5.4 1.6 1.0 2.6 8.0 
2007 4 95.0 3.1 0.9 0.9 1.8 5.0 
2008 5 90.7 5.5 0.9 2.9 3.8 9.3 
2009 4 93.2 1.8 3.2 1.8 5.0 6.8 
2010 4 90.9 5.4 2.7 0.7 3.4 8.8 
2011 2 96.5 1.4 0.0 2.1 2.1 3.5 
2012 4 91.1 1.5 6.7 0.7 7.4 8.9 
Eu
ro
pe
 
2001 47 91.3 5.7 2.7 0.3 3.0 8.7 Albania, Belgium,  
Bulgaria (2), Croatia, 
Czech Republic, 
Denmark (2), Estonia, 
France, Greece (3), 
Hungary, Ireland,  
Italy (10), Lithuania, 
Luxembourg, Malta, 
Poland (3), Serbia,  
Slovakia (2), Slovenia, 
Turkey (2), United 
Kingdom 
2002 57 92.7 5.2 1.2 0.9 2.1 7.3 
2003 64 92.9 3.8 1.0 2.3 3.3 7.1 
2004 58 93.5 4.3 1.4 0.8 2.2 6.5 
2006 54 88.7 7.0 3.8 0.6 4.4 11.3 
2007 49 94.2 3.7 1.6 0.4 2.0 5.7 
2008 51 91.2 4.4 2.5 1.9 4.4 8.8 
2009 40 95.1 2.6 1.3 0.9 2.2 4.8 
2010 39 92.4 4.1 1.2 2.3 3.5 7.6 
2011 36 92.5 4.5 1.7 1.3 3.0 7.5 
2012 40 95.5 2.8 1.2 0.4 1.7 4.5 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial susceptibility testing 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2012 iteration 
N
or
th
 A
m
er
ic
a 
 
2001 4 95.8 3.8 0.0 0.4 0.4 4.2 
Canada (6), United States 
of America (4) 
2002 3 90.5 6.9 0.6 2.0 2.6 9.5 
2003 7 93.4 5.2 0.0 1.4 1.4 6.6 
2004 9 94.2 4.2 1.8 0.0 1.8 6.0 
2006 8 94.8 2.9 1.0 1.3 2.3 5.2 
2007 10 95.4 2.9 0.8 0.8 1.6 4.6 
2008 14 96.4 0.6 0.4 2.6 3.0 3.6 
2009 10 98.7 0.0 0.4 0.9 1.3 1.3 
2010 11 94.8 2.6 0.2 2.4 2.6 5.2 
2011 9 92.1 2.6 1.5 3.8 5.3 7.9 
2012 10 96.0 2.1 1.0 0.9 1.9 4.0 
O
ce
an
ia
  
2001 6 91.8 4.7 2.7 0.9 3.6 8.2 
Australia (3). New Zealand 
 
2002 7 91.7 6.2 0.0 2.0 2.0 8.3 
2003 9 94.3 2.5 1.2 2.0 3.2 5.7 
2004 11 97.1 2.5 0.3 0.1 0.4 2.9 
2006 7 93.4 4.6 0.9 1.1 2.0 6.6 
2007 1 98.9 1.1 0.0 0.0 0.0 1.1 
2008 4 93.9 3.8 0.0 2.3 2.3 6.1 
2009 4 95.9 3.2 0.3 0.6 0.9 4.1 
2010 4 92.5 4.6 0.6 2.3 2.9 7.5 
2011 4 93.8 5.6 0.6 0.0 0.6 6.2 
2012 4 95.5 3.1 0.6 0.9 1.4 4.5 
R
us
si
a 
 
2001 1 81.9 15.3 2.8 0.0 2.8 18.1 
Belarus. Russian 
Federation (4). Ukraine 
 
2002 1 84.5 9.9 5.6 0.0 5.6 15.5 
2003 1 100.0 0.0 0.0 0.0 0.0 0.0 
2004 4 91.2 6.6 1.5 0.7 2.2 8.8 
2006 5 87.4 8.2 2.7 1.7 4.4 12.6 
2007 8 88.9 5.8 4.8 0.4 5.2 11.0 
2008 6 92.2 4.7 1.4 1.7 3.1 7.8 
2009 6 93.8 2.1 3.3 0.8 4.1 6.2 
2010 8 94.3 3.3 1.3 1.1 2.4 5.7 
2011 7 90.0 4.8 3.2 2.0 5.2 10.0 
2012 6 97.4 2.0 0.0 0.6 0.6 2.6 
La
tin
 A
m
er
ic
a 
 
 
2001 11 90.8 6.9 1.4 1.0 2.4 9.2 
Argentina. Belize.  
Brazil (2). Chile (2). 
Colombia (3). Costa Rica. 
Ecuador (2). Granada. 
Guatemala (2). Honduras. 
Mexico. 
Nicaragua. Panama. 
Paraguay. Peru. 
Suriname. Uruguay. 
Venezuela 
2002 13 93.7 4.6 0.7 1.0 1.7 6.3 
2003 12 90.8 4.2 2.0 3.0 5.0 9.2 
2004 17 94.4 4.7 0.8 0.1 0.9 5.6 
2006 16 88.7 6.3 4.5 0.6 5.1 11.3 
2007 17 94.9 1.8 1.9 1.4 3.3 5.0 
2008 20 93.0 3.4 1.5 2.1 3.6 7.0 
2009 20 95.6 2.1 1.1 1.2 2.3 4.4 
2010 23 90.8 2.1 5.6 1.4 7.1 9.2 
2011 22 90.8 2.8 3.1 3.3 6.4 9.2 
2012 25 94.4 1.6 3.0 1.0 4.0 5.6 
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Table 9 (continued). Region-based categorization of EQAS participants’ performance of Salmonella antimicrobial susceptibility testing. 
Region EQAS 
iteration 
No. 
of 
labs 
 
% correct 
test result 
 
 
 
% minor 
deviations  
(S ↔ I or 
I ↔ R)^ 
 
% major 
deviations 
(S → R)^ 
 
% very 
major 
deviations 
(R → S)^ 
 
% critical 
deviations 
(S → R & 
R → S)^ 
 
% total 
deviations 
(S→R & R→S 
& S↔I or 
I↔R)^ 
Countries participating 
in the 2012 iteration 
C
hi
na
 
 
2001 4 98.9 0.8 0.0 0.3 0.3 1.1 
China (9) 
 
2002 3 96.0 4.0 0.0 0.0 0.0 4.0 
2003 8 90.1 3.6 2.8 3.6 6.4 10.0 
2004 8 96.0 3.2 0.7 0.1 0.8 4.0 
2006 6 89.6 7.0 2.9 0.5 3.4 10.4 
2007 10 98.3 1.1 0.3 0.2 0.5 1.6 
2008 18 92.8 3.7 0.8 2.7 3.5 7.2 
2009 14 94.8 2.2 2.1 0.8 2.9 5.1 
2010 9 92.1 4.5 1.6 1.8 3.4 7.9 
2012 9 95.3 3.0 0.5 1.2 1.6 4.7 
So
ut
he
as
t A
sia
  
2001 16 88.1 7.7 2.3 1.9 4.2 11.9 
 
 
Brunei Darussalam. 
Cambodia. India (12). 
Japan (2).  
Korea Rep. Of (2).  
Lao P.´s Dem. Rep..  
Malaysia (3). Nepal. 
Philippines. Sri Lanka. 
Taiwan. Thailand (5).  
Viet Nam (4) 
2002 18 89.0 8.1 1.4 1.6 3.0 11.0 
2003 17 87.4 5.2 4.7 2.7 7.4 12.6 
2004 16 92.8 4.4 2.3 0.5 2.8 7.2 
2006 15 90.0 8.1 1.2 0.8 2.0 10.0 
2007 20 93.9 4.0 1.4 0.7 2.1 6.1 
2008 19 90.5 4.7 2.2 2.6 4.8 9.5 
2009 27 91.8 4.1 3.0 1.2 4.2 8.3 
2010 25 92.8 3.8 1.5 1.9 3.4 7.2 
2011 26 90.5 3.5 2.4 3.5 5.9 9.5 
2012 35 91.7 3.9 3.5 0.9 4.4 8.3 
^S. susceptible; I. intermediate; R. resistant 
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Table 10. EQAS participants’ performance of antimicrobial susceptibility testing of quality control strain Escherichia coli ATCC 25922 
 Method 
Perfor-
mance5.6 AMC AMP CAZ CHL CIP POD CRO CTX ENR
2 FFN2 FIS (SMX)3 GEN NAL STR SXT TET TMP XNL
2 
Accepted 
interval1 
MIC (μg/ml)    2-8 2-8 0.06-0.5 2-8 0.004-0.016 
0.25-
1 
0.03-
0.12 
0.03-
0.12 
0.008-
0.03 2-8 8-32 0.25-1 1-4 4-16
4 ≤0.5/9.5 0.5-2 0.5-2 0.25-1 
Disks (mm)   18-24 16-22 25-32 21-27 30-40 23-28 29-35 29-35 32-40 22-28 15-23 19-26 22-28 12-20 23-29 18-25 21-28 26-31 
EQ
A
S 
ite
ra
tio
n 
(to
ta
l n
o.
 o
f p
ar
tic
ip
an
ts
) 
2000 
(44) 
MIC & Disk No.
5 - 37 - 38 35 - - - - - 19 39 37 36 - 42 31 - 
%6 - 27 - 37 20 - - - - - 53 23 35 22 - 42 30 - 
2001 
(107) 
MIC & Disk No.
5 - 97 - 97 97 - - - - - 53 99 74 81 90 96 50 - 
%6 - 19 - 20 14 - - - - - 34 12 14 12 14 22 22 - 
2002 
(114) 
MIC & Disk No.
5 - 109 - 107 108 - - - - - 57 108 102 82 102 102 66 - 
%6 - 16 - 15 14 - - - - - 26 12 14 11 12 13 11 - 
2003 
(144) 
MIC & Disk No.
5 - 140 - 137 138 - - - - - 82 138 132 105 129 137 79 - 
%6 - 14 - 22 9 - - - - - 17 9 16 9 14 19 14 - 
2004 
(140) 
MIC & Disk No.
5 117 132 - 128 132 - - 111 - - 84 134 126 110 120 129 87 - 
%6 13 10 - 13 8 - - 18 - - 16 10 9 6 11 13 9 - 
2006 
(137) 
MIC & Disk No.
5 116 133 96 126 127 39 - 115 19 - 74 131 122 106 122 125 74 32 
%6 9 14 15 18 8 12 - 21 63 - 29 14 20 11 19 12 17 22 
2007 
(126) 
MIC & Disk No.
5 102 124 92 123 121 47 - 104 - 13 64 124 120 97 107 117 67 35 
%6 8 11 9 14 12 9 - 16 - 0 22 6 7 6 13 7 10 11 
2008 
(147) 
MIC & Disk No.
5 - 147 111 135 144 - - 124 - - 71 145 136 101 129 139 79 - 
%6 - 12 9 10 8 - - 14 - - 14 8 8 12 13 7 13 - 
MIC No.
5 - 33 23 24 33 - - 23 - - 18 31 23 19 22 28 16 - 
%6 - 0 5 0 6 - - 9 - - 11 0 0 11 9 0 13 - 
Disk No.
5 - 114 89 112 111 - - 101 - - 53 114 113 82 107 111 63 - 
%6 - 16 10 12 8 - - 15 - - 15 11 10 12 14 9 13 - 
2009 
(129) 
MIC & Disk No.
5 - 128 100 121 124 - 88 107 - - 63 123 117 98 113 122 70 - 
%6 - 16 13 15 7 - 16 10 - - 11 18 13 10 14 14 11 - 
MIC (27) No.
5 - 27 19 24 26 - 20 20 - - 14 25 24 19 21 27 25 - 
%6 - 11 11 8 8 - 15 15 - - 21 12 8 5 19 11 13 - 
Disk (102) No.
5 - 101 81 97 98 - 68 87 - - 49 98 93 79 92 95 55 - 
%6 - 16 14 16 6 - 16 9 - - 10 18 14 11 12 15 11 - 
2010 
(116) 
MIC & Disk No.
5 - 114 97 108 115 - 79 100 - - 51 112 104 84 101 110 63 - 
%6 - 11 9 9 6 - 10 14 - - 11 11 5 5 12 5 15 - 
MIC (25) No.
5 - 25 15 21 25 - 15 17 - - 12 24 19 17 17 24 11 - 
%6 - 12 20 10 8 - 7 18 - - 8 13 16 18 18 17 36 - 
Disk (91) No.
5 - 89 82 87 90 - 64 83 - - 39 88 85 67 84 86 52 - 
%6 - 9 6 8 4 - 9 11 - - 10 9 2 1 10 1 8 - 
2011 
(112) 
MIC & Disk No. - 
5 111 89 102 109 - 76 96 - - 50 103 103 72 99 107 51 - 
% - 6 17 4 11 7 - 7 9 - - 8 11 8 4 16 7 14 - 
MIC (23) No. - 
5 23 15 18 22 - 16 15 - - 13 22 19 17 16 21 11 - 
% - 6 4 7 0 9 - 6 0 - - 8 9 0 6 6 5 0 - 
Disk (89) No. - 
5 88 74 84 87 - 60 81 - - 37 81 84 55 83 86 40 - 
% - 6 20 4 13 7 - 7 11 - - 8 11 10 4 18 8 18 - 
2012 
(135) 
MIC & Disk No.
5 - 134 111 121 131 - 90 115 - - 53 127 121 89 112 129 66 - 
%6 - 13 12 7 6 - 11 10 - - 11 9 9 8 13 10 21 - 
MIC (37) No.
5 - 37 26 31 35 - 23 28 - - 19 35 31 26 23 35 22 - 
%6 - 3 4 0 3 - 0 4 - - 5 3 3 8 0 0 9 - 
Disk (98) No.
5 - 97 85 90 96 - 67 87 - - 34 92 90 63 89 94 44 - 
%6 - 16 14 9 7 - 15 11 - - 15 11 11 8 16 14 27 - 
 16 
 
 
Legend table 10 
0For antimicrobial abbreviations: see List of Abbreviations page 1 
1CLSI standard. Performance Standards for Antimicrobial Disk and Dilution Susceptibility testing. 22nd Informational supplement. CLSI document M100-S22. 2012 Wayne. PA. USA 
2CLSI standard. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for bacteria Isolated from Animals. M31-A3. 3rd Edition [Approved Standard]. 2008. 
Wayne. PA. USA 
3FIS (sulfisoxazole) covers the group of SMX (sulfonamides) 
4Quality control range developed by the manufacturer of Sensititre 
5No.. number of laboratories performing the analysis 
6
-. not determined 
%. percentage of laboratories reporting erroneous results 
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Table 11. Shigella serotypes (ST) and deviations (D). WHO EQAS 2012 
*number of participants reporting deviating result  
 
 
 
 
 
 
 
 
 
Strain Correct 
serotype 
 
No. of labs 
reporting 
correct 
identification 
D (%) Deviating 
results (*) 
No. of labs 
reporting 
correct ST 
D (%) Deviating 
results (*) 
WHO 
SH-12.1 
S. flexneri 
serotype 6 122 3,2 4 80 3,6 
1 (1), 1b (1), 4 
(1) 
WHO 
SH-12.2 
S.  flexneri 
var. X 127 0,8 1 68 12,8 
5 (3), 2b (2), 5b 
(2), 1b (1), 3 (1), 
var Y (1) 
WHO 
SH-12.3 
S.  flexneri 
serotype 1a 128 0,0  66 19,5 
1 (13), 1b (1), 3b 
(1), var Y (1) 
WHO 
SH-12.4 
S. flexneri 
serotype 1b 126 0,8 1 64 22,9 
1 (13), var Y (2), 
1a (1), 3 (1), 3b 
(1), 6 (1) 
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Table 12. Region-based categorization of laboratories performing Shigella serotyping in 2012 
 
Region Year No. of 
laboratories 
No. of strains 
serotyped 
Strains serotyped 
correctly (%) 
Countries participating in the 2012 iteration 
Africa 
2009 8 18 72.2 
Kenya, Mauritius, South Africa, Tunisia, Zimbabwe 2010 7 16 62.5 2011 4 10 100.0 
2012 5 18 90.0 
Central Asia & 
Middle East  
2009 3 5 100.0 
Israel, Jordan, Oman 2010 3 6 83.3 2011 2 6 100.0 
2012 3 9 81.8 
China 
2009 13 35 100.0 
China 2010 9 23 91.3 2011 - - - 
2012 8 29 90.6 
Caribbean 
2009 - - - 
Trinidad and Tobago 
 
2010 - - - 
2011 - - - 
2012 1 1 33.3 
Europe  
2009 15 40 92.5 Albania, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Germany, 
Greece, Ireland, Italy, Lithuania, Luxembourg, Malta, Serbia, Slovenia, Spain, 
Sweden, Turkey, United Kingdom 
2010 15 35 85.7 
2011 16 42 92.9 
2012 19 63 86.3 
North America  
2009 7 18 100.0 
Canada (6), United States of America (2) 2010 7 20 100.0 2011 6 16 100.0 
2012 8 25 80.6 
Oceanic  
2009 3 8 100.0 
Australia (2), New Zealand 2010 3 8 100.0 2011 3 8 100.0 
2012 3 12 100.0 
Russia  
2009 6 18 83.3 
Belarus, Russian Federation (3), Ukraine 2010 7 20 75.0 2011 6 18 88.9 
2012 5 16 80.0 
Latin America  
2009 16 40 97.5 Argentina, Bolivia, Brazil, Chile (2), Colombia, Costa Rica, Ecuador, El 
Salvador, Grenada, Guatemala, Honduras, Mexico, Nicaragua, Panama (2), 
Paraguay, Peru, Venezuela 
2010 13 33 78.8 
2011 15 37 94.6 
2012 19 58 80.6 
Southeast Asia  
2009 11 30 90.0 India,  Japan (2), Korea Rep. of, Lao P.´s Dem. Rep., Malaysia, Nepal, 
Philippines, Taiwan, Thailand (4) 
 
2010 14 32 87.5 
2011 13 33 84.8 
2012 14 47 90.4 
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Table 13. EQAS participating laboratories’ performance of Shigella strains antimicrobial susceptibility testing  
 
EQAS iteration No. of 
participating 
laboratories 
% correct test 
results 
% minor 
deviations 
(S ↔ I or I ↔ R)^ 
% major 
deviations 
(S → R)^ 
% very major 
deviations 
(R → S)^ 
% critical 
deviations 
(S → R & R → S )^ 
% total 
deviations 
(S → R & R → S & 
S ↔ I or I ↔ R)^ 
2008 15 95 2 2 1 3 5 
2009 111 96 2 1 1 2 4 
2010 114 91 2 1 6 7 9 
2011 107 92 2 1 4 5 7 
2012 120 91 3 1 5 6 9 
^S. susceptible; I. intermediate; R. resistant 
 
 
Table 14. Antimicrobial susceptibility test results (number of R/I/S) for the EQAS 2012 Shigella strains* 
 
Strain Antimicrobial∞ 
AMP CTX CAZ CRO CHL CIP GEN NAL STR SMX SXT TET TMP 
WHO SH-12.1 4/4/106 2/2/95 2/0/91 1/2/80 1/1/103 1/1/113 5/1/100 2/1/106 4/26/40 0/1/48 0/1/97 1/2/103 0/0/53 
WHO SH-12.2 114/1/1 3/2/96 1/0/94 2/0/83 92/9/6 64/7/46 6/2/100 108/1/2 69/1/4 2/0/47 10/5/84 100/1/6 51/1/2 
WHO SH-12.3 115/0/2 2/2/96 0/0/95 0/1/84 90/13/5 63/6/48 5/2/101 108/2/1 71/2/1 49/0/0 96/0/3 102/1/3 51/2/1 
WHO SH-12.4 5/1/109 1/1/98 0/0/93 0/1/83 93/2/12 45/1/69 5/1/102 106/3/2 32/23/18 48/0/1 87/1/12 89/5/13 51/2/1 
∞
*In bold: expected interpretation. Grey cell: <90% of laboratories did correct interpretation. R. resistant; I. intermediate; S. susceptible. 
For antimicrobial abbreviations: see List of Abbreviations page 1 
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Table 15. EQAS laboratories’ performance of Shigella strains antimicrobial susceptibility testing categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs 
Lab 
performance 
Antimicrobial 
AMP CAZ CHL CIP CTX GEN NAL SMX STR SXT TET TMP CRO OVERALL 
2008 15 
No. of tests 52 44 51 48 48 50 52 7 27 52 52 4 42 529 
% critical deviations* 1 2 1 - 2 1 - - 4 2 4 - 2 1.5 
% total deviations^ 1 2 1 - 2 1 - - 9 2 8 - 2 2.2 
2009 111 
No. of tests 423 358 388 426 372 396 388 211 293 388 386 218 301 4,548 
% critical deviations* 2.4 0.3 2.1 0.2 1.1 2.5 0.5 3.8 5.8 2.3 2.8 1.8 0.3 1.9 
% total deviations^ 3.8 0.3 4.6 0.9 1.1 3.5 1.5 3.8 18.1 3.6 7.5 1.8 0.6 3.8 
2010 114 
No. of tests 424 344 402 434 377 403 382 194 275 363 410 218 291 4,517 
% critical deviations* 1.7 0.6 3.5 40.8 2.4 3.5 2.1 4.6 8.0 8.3 4.4 3.7 0.0 6.4 
% total deviations^ 1.9 1.2 9.2 77.9 3.0 5.5 3.0 6.0 14.6 13.8 5.9 3.8 0.0 11.2 
2011 107 
No. of tests 403 322 353 396 343 359 369 179 246 371 376 178 289 4,184 
% critical deviations* 5.5 5.2 2.2 38.9 2.7 3.3 4.0 1.7 3.6 3.2 2.7 2.2 2.0 5.5 
% total deviations^ 7.7 12.0 4.2 40.7 2.7 4.4 11.0 1.7 10.5 3.2 3.5 2.2 2.0 7.7 
2012 120 
No. of tests 462 376 427 464 400 430 442 196 291 396 426 215 337 4,862 
% critical deviations* 2,6 0,8 5,6 35,3 2,0 4,9 1,6 1,5 9,3 6,3 5,4 1,9 0,9 6,0 
% total deviations^ 3,9 0,8 11,5 38,6 3,8 6,3 3,2 2,0 27,1 8,1 7,5 4,2 2,1 9,2 
∞For antimicrobial abbreviations: see List of Abbreviations page 1 
*R→ S & S → R (R. resistant; S. susceptible) 
^S→R & R→S & S↔I or I↔R (I. intermediate) 
-. not determined
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Table 16. Region-based categorization of EQAS participating laboratories’ performance of antimicrobial susceptibility tests for Shigella strains 
 
Region Year No. of 
labs 
 
% correct 
test result 
% minor 
deviations 
(S↔I or I↔R)^ 
% major 
deviations 
(S→R)^ 
% very major 
deviations 
(R→ S)^ 
% critical 
deviations 
(R→ S & S → R)^ 
% total 
deviations 
(S→R & R→S & 
S↔I or I↔R)^ 
Countries participating in the 2012 
iteration 
Africa 
2009 17 93.3 2.4 3.5 0.8 4.3 6.8 Cameroon, Central African Republic, Congo, 
Rep. of, Côte d´Ivoire, Ethiopia, Kenya, 
Madagascar, Malawi, Mauritius, Nigeria (2), 
Senegal, South Africa, Sudan, Tunisia, Zambia, 
Zimbabwe 
2010 16 84.8 2.5 2.7 10.0 12.7 15.2 
2011 16 86.0 1.8 3.6 8.3 11.9 13.7 
2012 17 82.6 4.2 2.5 10.7 13.2 17.4 
Central Asia 
& Middle 
East  
2009 5 94.8 0.9 3.0 1.3 4.4 5.2 
Iran Islamic Republic of (2). Israel, Jordan,  
Oman (2) 
2010 6 90.6 1.2 1.6 6.7 8.3 9.4 
2011 4 92.9 1.6 0.5 4.9 5.4 7.1 
2012 6 92.3 4.0 2.0 1.3 3.4 7.4 
Caribbean  
2009 4 95.6 1.5 0.7 2.2 2.9 4.4 
Barbados, Jamaica, Trinidad and Tobago 
2010 4 88.5 1.5 3.8 6.2 10.0 11.5 
2011 1 97.7 2.3 0.0 0.0 2.3 2.3 
2012 3 84.6 1.9 7.7 5.8 13.5 15.4 
Europe  
2009 22 98.1 1.1 0.7 0.1 0.8 1.9 Albania, Belgium, Bulgaria, Croatia, Czech 
Republic, Denmark (2), Greece (2), Ireland,  
Italy (3), Lithuania, Luxembourg, Malta, Poland 
(2), Serbia, Slovakia, Slovenia, Spain, Turkey, 
United Kingdom 
2010 27 93.6 1.5 0.9 3.9 4.8 6.4 
2011 24 94.8 2.2 0.5 2.5 3.0 5.1 
2012 24 96.6 1.7 0.4 1.4 1.7 3.4 
North 
America  
2009 6 100.0 0.0 0.0 0.0 0.0 0.0 
Canada (6). United States of America (2) 
2010 7 95.0 0.0 0.0 5.0 5.0 5.0 
2011 4 90.1 0.7 3.3 5.9 9.2 9.9 
2012 6 89.5 0.0 2.1 8.4 10.5 10.5 
Oceanic  
2009 - - - - - - - 
Australia 
2010 1 90.0 10.0 0.0 0.0 0.0 10.0 
2011 1 92.5 5.0 0.0 2.5 2.5 7.5 
2012 1 90.0 7.5 0.0 2.5 2.5 10.0 
Russia  
2009 6 95.5 1.6 1.6 1.3 2.9 4.6 
Belarus, Russian Federation (4), Ukraine 
2010 7 92.1 2.9 1.5 3.5 5.0 7.9 
2011 6 94.4 3.6 0.0 2.0 2.0 5.6 
2012 5 96.8 1.4 0.5 1.4 1.8 3.2 
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Table 16 (continued) Region-based categorization of EQAS participating laboratories’ performance of antimicrobial susceptibility tests for Shigella strains 
 
Latin 
America  
2009 20 98.3 1.1 0.4 0.3 0.7 1.7 Argentina, Belize, Bolivia, Brazil (2), Chile (2),  
Colombia, Costa Rica, Ecuador (2), El Salvador,  
Grenada, Guatemala (2), Honduras, Mexico, 
Nicaragua, Panama, Paraguay, Peru, Suriname, 
Uruguay, Venezuela 
2010 22 92.1 1.3 2.1 4.5 6.6 7.9 
2011 20 94.0 1.5 1.3 3.2 4.5 6.0 
2012 24 91.7 1.3 0.6 6.5 7.1 8.3 
Southeast 
Asia  
2009 18 94.1 3.9 0.3 1.7 2.0 5.9 
Cambodia, India (11), Japan (2), Korea Rep. Of, 
Lao P.´s Dem. Rep., Malaysia, Nepal, Philippines 
Taiwan, Thailand (4), Viet Nam (3). 
 
2010 16 90.5 2.4 0.7 6.4 7.1 9.5 
2011 19 90.0 2.1 0.8 6.1 6.9 9.0 
2012 27 87.1 5.1 1.9 5.6 7.6 12.7 
China 
2009 12 96.3 2.2 1.0 0.5 1.5 3.7 
China 
2010 8 92.7 1.2 0.6 5.5 6.1 7.3 
2011 - - - - - - - 
2012 7 90.3 2.9 0.0 6.8 6.8 9.7 
^S. susceptible; I. intermediate; R. resistant. 
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Table 17. Proportion of laboratories that obtained the expected result. Number (n/N) and percentages of 
laboratories which correctly detected and confirmed the ESBL and non ESBL producing Salmonella and 
Shigella strains. 
 
Isolate no. Expected interpretation Confirmatory tests 
CAZ/Cl:CAZ CTX/Cl:CTX 
WHO S-12.1 non ESBL 23/23 (100%) 23/23 (100%) 
WHO S-12.2 non ESBL 23/23 (100%) 22/23 (96%) 
WHO S-12.3 non ESBL 5/5 (100%) 6/6 (100%) 
WHO S-12.4 non ESBL 23/23 (100%) 25/26 (96%) 
WHO S-12.5 non ESBL 24/24 (100%) 26/26 (100%) 
WHO S-12.6 non ESBL 21/21 (100%) 23/23 (100%) 
WHO S-12.7 non ESBL 20/21 (95%) 22/23 (96%) 
WHO S-12.8 non ESBL 22/22 (100%) 23/25 (92%) 
WHO SH-12.1 non ESBL 18/18 (100%) 19/20 (95%) 
WHO SH-12.2 non ESBL 20/20 (100%) 23/24 (96%) 
WHO SH-12.3 non ESBL 19/20 (95%) 23/23 (100%) 
WHO SH-12.4 non ESBL 17/17 (100%) 19/19 (100%) 
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Table 18. EQAS participating laboratories’ performance of Campylobacter strains identification 
 
EQAS 
iteration 
No. of 
labs 
Correct species Strain no. No. of 
results 
submitted 
% correct 
identification 
Deviating results (*) 
2003 
97 C. jejuni # 1 93 88%  C. coli (9) C. lari (3) 
97 C. coli # 2 93 84%  
C. jejuni (7) 
C. lari (4) 
C. upsaliensis (4) 
2004 
109 C. lari # 1 97 79%  C. coli (11) C. jejuni (8) 
109 C. jejuni # 2 109 87%  
C. coli (8) 
C. lari (4) 
C. upsaliensis (2) 
2006 
99 C. jejuni # 1 87  90% 
C. lari (3) 
C. coli (3) 
C. upsaliensis (3) 
99 C. coli # 2 95  65%  
C. lari (19) 
C. jejuni (11) 
C. upsaliensis (2) 
2007 
142 C. lari # 1 98  74% 
C. jejuni (10) 
C. coli (9) 
C. upsaliensis (7) 
142 C. coli # 2 102  76%  
C. lari (3) 
C. jejuni (20) 
C. upsaliensis (2) 
2008 
154 C. lari # 1 109 62% 
C. coli (14) 
C. jejuni (18) 
C. upsaliensis (7) 
154 C. lari # 2 109 62% 
C. coli (10) 
C. jejuni (19) 
C. upsaliensis (13) 
2009 
131 C. coli # 1 87 77% 
C. upsaliensis (10) 
C. jejuni (9) 
C. lari (1) 
131 C. jejuni # 2 87 95% C. upsaliensis (3) C. lari (1) 
2010 
130 C. jejuni # 1 88 92% 
C. coli (4)  
C. lari (3) 
C. upsaliensis (1) 
130 C. coli # 2 84 85% 
C. jejuni (11)  
C. lari (2)  
C. upsaliensis (2) 
2011 
132 C. coli # 1 81 59% 
C. jejuni (19)  
C. lari (13)  
C. upsaliensis (1) 
132 C. coli # 2 79 70% 
C. jejuni (17)  
C. lari (5)  
C. upsaliensis (2) 
2012 
135 C. jejuni # 1 112 96% C. coli (4) 
135 C. jejuni # 2 103 85% 
C. coli (10)  
C. lari (5)  
C. upsaliensis (1) 
*number of participants reporting the specified deviating result 
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Table 19. Region-based categorization of EQAS 2012 participating laboratories’ performance of 
Campylobacter strains identification 
Region Year No. of labs 
No. of strains 
identified 
% strains 
correctly 
identified 
Countries participating in the 2012 iteration 
Africa 
2009 9 15 53 
Cameroon, Central African Republic, Kenya, 
Madagascar, Malawi, Mauritius, South Africa, 
Sudan, Tunisia 
2010 7 13 77 
2011 10 19 32 
2012 9 17 82 
Central Asia & 
Middle East 
2009 14 27 85 
China (8), Iran (Islamic rep. of), Israel, Oman 
2010 13 26 89 
2011 2 4 50 
2012 11 22 96 
Caribbean 
2009 2 4 100 
Barbados, Grenada, Jamaica, Trinidad and Tobago 
2010 3 6 67 
2011 1 2 0 
2012 4 7 57 
Europe 
2009 29 55 89 Bulgaria (2), Croatia, Cyprus, Czech Republic, 
Denmark, Estonia, Germany, Greece, Hungary,  
Italy (9), Lithuania, Luxembourg, Malta, Poland (2), 
Serbia, Slovakia, Slovenia, Spain, Turkey 
2010 29 57 97 
2011 25 48 85 
2012 29 56 95 
North America 
2009 10 19 90 
Canada (9), United States of America (4) 
2010 11 22 86 
2011 9 18 78 
2012 13 26 96 
Oceania 
2009 2 4 100 
Australia, New Zealand 
2010 2 3 100 
2011 2 4 100 
2012 2 4 100 
Russia 
2009 2 4 100 
Belarus, Russian Federation (3), Ukraine 
2010 2 4 100 
2011 2 4 50 
2012 5 10 80 
Latin America 
2009 14 26 89 Argentina, Brazil (2), Chile (2), Colombia (3), Costa 
Rica, Ecuador, El Salvador, Guatemala, Mexico, 
Panama, Paraguay (2), Peru (2), Suriname, Uruguay, 
Venezuela (2)  
2010 19 37 78 
2011 19 37 49 
2012 22 40 95 
Southeast Asia 
2009 10 20 90 
Brunei Darussalam, Cambodia, India (2), Japan (2), 
Korea (Rep. of) (2), Lao P.´s Dem. Rep., Malaysia, 
Philippines, Sri Lanka, Taiwan, Thailand (4) 
2010 14 27 93 
2011 12 24 67 
2012 17 33 85 
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Table 20. EQAS participants’ performance of Campylobacter strains antimicrobial susceptibility 
testing 
 
EQAS 
iteration 
No. of 
labs  
% correct 
test results 
 
% major 
deviations 
(S → R)^ 
% very major 
deviations 
(R → S)^ 
% critical 
deviations 
(R → S & S → R)^ 
2009 25 91.4 4.5 4.1 8.6 
2010 37 91.3 4.2 4.5 8.7 
2011 38 93.8 2.8 3.4 6.2 
2012 47 93.6 5.0 1.5 6.4 
^S. susceptible; R. resistant 
 
 
Table 21. Antimicrobial susceptibility test results (number of R/S) for the EQAS 2012 
Campylobacter strains* 
 
 
 
 
 
 
 
 
 
^For antimicrobial abbreviations. see List of Abbreviations page 1 
*In bold: expected interpretation. R. resistant; S. susceptible 
§ 
 
Results for the combination WHO C-12.1 and NAL were disregarded due to conflicting results 
that indicated a problem with the expected result.  
 
Table 22. EQAS participants’ performance of Campylobacter antimicrobial susceptibility testing 
categorized by antimicrobial 
 
EQAS 
iteration 
No. of 
labs 
Lab 
performance 
Antimicrobial 
CHL CIP ERY GEN NAL STR TET 
2009 
 
25 
 
No. of tests 37 46 46 43 41 34 45 
% critical deviations* 8.1 6.5 10.9 2.3 9.8 11.8 11.1 
2010 
 
37 
No. of tests 44 70 71 59 53 39 68 
% critical deviations* 4.5 7.1 11.3 10.2 7.5 10.3 8.8 
2011 
 
38 
No. of tests 41 67 62 65 62 30 60 
% critical deviations* 0.0 6.0 6.5 3.1 8.1 13.3 8.3 
2012 
 
47 
No. of tests 70 84 81 81 39 53 74 
% critical deviations* 4.3 6.0 6.2 7.4 5.1 11.3 5.4 
^For antimicrobial abbreviations. see List of Abbreviations page 1 
*R→ S & S → R (R. resistant; S. susceptible 
 
  
Strain 
Antimicrobial^ 
CHL CIP ERY GEN NAL STR TET 
WHO 
C-12.1 1/35 39/4 5/37 3/39 § 24/3 4/34 
WHO 
C-12.2 2/32 40/1 39/0 3/36 37/2 3/23 36/0 
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Table 23. Region-based categorization of EQAS 2012 participants’ performance of 
antimicrobial susceptibility testing of Campylobacter strains 
 
Region Year No. of 
labs 
% correct 
test result 
% major 
deviations 
(S → R)^ 
% very 
major 
deviations 
(S → R)^ 
% critical 
deviations 
(R→S & 
S→R)^ 
Countries participating 
in the 2012 iteration 
 
 
Africa 
2009 2 75.0 10.7 14.3 25.0 
Cameroon, Central African 
Republic, Sudan, Tunisia 
2010 2 95.2 0.0 4.8 4.8 
2011 7 85.0 3.3 11.7 15.0 
2012 4 94.3 0.0 5.7 5.7 
Central Asia 
& Middle East 
2009 0 - - - - 
Iran (Islamic Republic of), 
Oman 
2010 0 - - - - 
2011 1 75.0 0.0 25.0 25.0 
2012 2 93.8 6.3 0.0 6.3 
China 
2009 2 95.2 4.8 0.0 4.8 
China (2), 
2010 1 100.0 0.0 0.0 0.0 
2011 0 - - - - 
2012 2 88.5 7.7 3.8 11.5 
Caribbean 
2009 0 - - - - 
Country X 
2010 0 - - - - 
2011 0 - - - - 
2012 1 75.0 25.0 0.0 25.0 
Europe 
2009 10 94.8 3.0 2.2 5.2 Bulgaria (2), Denmark (2), 
Greece, Hungary, Italy (3), 
Luxembourg, Malta,  
Poland (2), Slovenia, Spain, 
Turkey 
2010 13 100.0 0.0 0.0 0.0 
2011 11 100.0 0.0 0.0 0.0 
2012 16 97.3 1.6 1.1 2.7 
North 
America 
2009 2 100.0 0.0 0.0 0.0 
Canada (2), United States 
of America (3) 
2010 5 93.8 6.3 0.0 6.3 
2011 5 100.0 0.0 0.0 0.0 
2012 5 100.0 0.0 0.0 0.0 
Oceania 
2009 0 - - - - 
- none -  
2010 0 - - - - 
2011 1 100.0 0.0 0.0 0.0 
2012 0 - - - - 
Russia 
2009 0 - - - - 
- none -  
2010 1 78.6 7.1 14.3 21.4 
2011 1 100.0 0.0 0.0 0.0 
2012 0 - - - - 
Latin America 
2009 5 93.2 6.8 0.0 6.8 
Argentina, Brazil, Chile (2), 
Costa Rica, Paraguay,  
Peru (2) 
2010 8 89.6 6.0 4.5 10.4 
2011 7 96.8 0.0 3.2 3.2 
2012 7 95.2 3.2 1.6 4.8 
Southeast Asia 
2009 4 84.4 4.4 11.1 15.6 India, Japan,  
Korea Rep. of (2), 
Malaysia, Philippines, 
Thailand (4) 
2010 7 77.2 9.8 13.0 22.9 
2011 5 85.1 9.0 6.0 14.0 
2012 10 85.8 13.3 0.9 14.2 
^S. susceptible; R. resistant 
 
  
Table 24. EQAS 2012 participants’ performance of antimicrobial susceptibility testing of 
Campylobacter jejuni ATCC 33560 
 
 
Method used Incubation conditions 
Labs’ 
performance1. 2 
Antimicrobial3 
CHL CIP ERY GEN NAL TET 
EQAS 
2010 
(N=20) 
Microdilution 42°C / 24h 
No. 3 1 6 6 6 4 6 
% 67 2 83 100 83 75 83 
Microdilution 36-37°C / 48h 
No. 5 1 8 8 8 7 8 
% 80 2 88 88 75 86 88 
Agardilution 42°C / 24h 
No. - 
1 6 6 6 - - 
% - 2 100 83 83 - - 
Agardilution 36-37°C / 48h 
No. - 1 0 0 0 - - 
% - 2 0 0 0 - - 
Overall Overall 
No. 8 1 20 20 20 11 14 
% 75 2 90 90 80 82 86 
EQAS 
2011 
(N=26) 
Microdilution 42°C / 24h 
No.1 4 9 9 8 7 9 
%2 100 67 100 88 100 67 
Microdilution 36-37°C / 48h 
No.1 6 8 6 8 7 7 
%2 83 88 100 75 86 86 
Agardilution 42°C / 24h 
No.1 - 8 8 8 - - 
%2 - 88 63 100 - - 
Agardilution 36-37°C / 48h 
No.1 - 1 1 1 - - 
%2 - 0 0 100 - - 
Overall Overall 
No.1 10 26 24 25 14 16 
%2 90 77 83 88 93 75 
EQAS 
2012 
(N=34) 
Microdilution 42°C / 24h 
No. 9 1 12 12 12 10 12 
% 67 2 75 83 83 80 75 
Microdilution 36-37°C / 48h 
No. 7 1 9 8 8 8 8 
% 100 2 89 100 63 88 88 
Agardilution 42°C / 24h 
No. - 1 9 7 9 - - 
% - 2 89 86 89 - - 
Agardilution 36-37°C / 48h 
No. - 1 4 4 4 - - 
% - 2 50 100 100 - - 
Overall Overall 
No. 34 1 80 75 78 43 50 
% 82 2 81 88 83 86 80 
1No.. number of labs performing the analysis 
2%. percentage of labs reporting correct results 
3
-. not determined 
For antimicrobial abbreviations: see List of Abbreviations page 1 
 
 
 
 
 
  
Table 25. EQAS participating laboratories’ performance of unknown strain identification  
* incorrect serovar 
 
 
EQAS 
iteration 
Strain ID No. of 
participating labs 
Percentage (%) of labs performing correct 
identification  
2003 E. coli O157 115 99 
2004 Shigella flexneri 121 94 (Shigella) 74 (S. flexneri) 
2006 Yersinia enterocolitica O3 134 
93 (Yersinia) 
89 (Y. enterocolitica) 
66 (Y. enterocolitica O3) 
2007 Vibrio parahaemolyticus 86 83  
2008 Enterobacter sakasakii 128 92  
2009 Vibrio mimicus 56 48  
2010 Citrobacter spp. 115 90 
2011 Aeromonas hydrophila 106 83 
2012 Salmonella Paratyphi B  var. Java 134 
23% (Salmonella spp) 
7% (Salmonella O:B) 
24% (Salmonella Paratyphi B var. java. 
In total 54% 
 
Deviations:  
Citrobacter freundii (1), Edwardsiella sp (1), 
Escherichia fergusonii (1), Proteus mirabilis 
(1), Salmonella serovar X* (24), Salmonella 
serovar Paratyphi B (34) 
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M00-06-001/01.12.2011 
Kgs. Lyngby, Denmark, April 2012 
 
SIGN-UP FOR EQAS 2012 
Greetings to the WHO Global Foodborne Infections Network (WHO GFN) Members: 
WHO GFN strives to increase the quality of laboratory-based surveillance of Salmonella and other 
foodborne pathogens by encouraging national and regional reference laboratories that attended 
WHO GFN training courses to participate in the External Quality Assurance System (EQAS). The 
2011 EQAS cycle is completed, and we are pleased to announce the launch of the 2012 EQAS 
cycle. 
 
EQAS provides the opportunity for proficiency testing which is considered an important tool for the 
production of reliable laboratory results of consistently good quality. 
WHY PARTICIPATE IN EQAS? 
 
This year, WHO EQAS offers the following components:  
WHAT IS OFFERED IN EQAS? 
- Serogrouping, serotyping and antimicrobial susceptibility testing of eight Salmonella isolates;  
- Serotyping and antimicrobial susceptibility testing of four Shigella isolates;  
- Species identification and antimicrobial susceptibility testing of two Campylobacter isolates;  
- Identification of one unknown bacterial isolate. 
 
All national and regional reference laboratories which perform analysis on Salmonella, Shigella 
and/or Campylobacter and are interested in participating in an external quality assurance program 
are invited to participate. 
WHO SHOULD PARTICIPATE IN EQAS 2012? 
We expect that all national and regional reference laboratories that attended WHO GFN Training 
Courses will participate in EQAS.  
The WHO GFN Regional Centers in cooperation with the EQAS Coordinator will evaluate the list 
of laboratories that sign up for EQAS 2012. Laboratories which signed up and received bacterial 
isolates in year 2011 but did not submit any result should provide a consistent explanation for this if 
they want to participate in 2012.  
 
There is no participation fee in EQAS 2012. Laboratories should, however, cover the expenses for 
parcel shipment if they can afford it. If FedEx has ‘Dangerous Goods-service’ in your country or if 
you have a DHL-account no, please provide your FedEx or DHL import account number (for 
import of UN3373 Biological Substance Category B) in the sign-up form or, alternatively, to the 
EQAS Coordinator (please find contact information below). We need this information at this stage 
to save time and resources. Participating laboratories are responsible for paying any expenses 
related to taxes or custom fees applied by their country.  
COST FOR PARTICIPATING IN EQAS 
 
HOW TO SIGN- UP FOR EQAS 2012 
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This link will open a sign-up webpage: http://thor.dfvf.dk/signup 
In this webpage, you will be asked to provide the following information: 
-       Name of institute, department, laboratory, and contact person 
-       Complete mailing address for shipment of bacterial isolates (no post-office box number) 
-       Telephone and fax number, e-mail address 
-       FedEx or DHL import account number (if available) 
-       Approximate number of Salmonella isolates annually serogrouped/serotyped 
-       Approximate number of Salmonella isolates annually tested for antimicrobial susceptibility 
-       Availability of ATCC reference strains 
-       Components of EQAS 2012 you plan to participate in 
-       Level of reference function in your country  
 
If you experience any problem in the sign-up webpage, please try again a few days later. If 
problems persist after several attempts, please contact the EQAS Coordinator Susanne Karlsmose: 
E-mail suska@food.dtu.dk; fax +45 3588 6341.  
 
Due to increased number of participants in WHO EQAS, a number of different institutions will ship 
the bacterial isolates, and you will receive information concerning the institution shipping your 
parcel. The bacterial isolates will be shipped between August and September 2012. 
TIMELINE FOR SHIPMENT OF ISOLATES AND AVAILABILITY OF PROTOCOLS 
In order to minimize delays, please send a valid import permit to the EQAS coordinator. Please 
apply for a permit to receive the following (according to your level of participation): “UN3373, 
Biological Substance Category B”: eight Salmonella strains, four Shigella strains, two 
Campylobacter, one Campylobacter reference strain (for new participants performing antimicrobial 
susceptibility testing on Campylobacter), one Escherichia coli reference strain (for new participants 
performing antimicrobial susceptibility testing on Salmonella and/or Shigella) and an unknown 
isolate (enteric bacteria) between August and September 2012. 
 
Protocols and all relevant information will be available for download from the website 
http://www.antimicrobialresistance.dk/233-169-215-eqas.htm. 
 
Results must be submitted to the National Food Institute (DTU Food) by 31
DEADLINE FOR SUBMITTING RESULTS TO THE NATIONAL FOOD INSTITUTE 
st
Deadline for sign-up for EQAS 2012 is 
 December 2012 
through the password-protected website. An evaluation report will be generated upon submission of 
results. Full anonymity is ensured, and only DTU Food and the WHO GFN Regional Centre in your 
region will have access to your results. 
30th May 2012 
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WHO 2012 S-12.1 Salmonella Wippra 6,8:z10:z6  =       2 SUSC <=   0.12 SUSC  =  0.125 SUSC  =   0.03 SUSC  =       8 SUSC  =    0.03 SUSC  =       0.5 SUSC  =       2 SUSC  =       16 INTER  =     128 SUSC <=       2 SUSC <=       1 SUSC  =   0.06 SUSC
WHO 2012 S-12.2 Salmonella Liverpool 1,3,19:d:e,n,z15 <=       1 SUSC <=   0.12 SUSC  =  0.125 SUSC  =   0.06 SUSC  =       4 SUSC  =    0.03 SUSC  =       0.5 SUSC  =       2 SUSC  =       16 INTER  =       32 SUSC <=       2 SUSC <=       1 SUSC  =   0.03 SUSC
WHO 2012 S-12.3 Salmonella Sundsvall 6,14,25:z:e,n,x <=       1 SUSC <=   0.12 SUSC  =   0.06 SUSC  =   0.03 SUSC  =       4 SUSC  =    0.03 SUSC  =     1 SUSC  =       4 SUSC  <=      8 SUSC  =       64 SUSC <=       2 SUSC <=       1 SUSC  =   0.06 SUSC
WHO 2012 S-12.4 Salmonella Enteritidis 9,12:g,m:-  =        4 SUSC  =   0.25 SUSC  =   0.06 SUSC <=   0.03 SUSC  =       8 SUSC  =    0.06 SUSC  >       16 RESIST  =       4 SUSC  =       64 RESIST  >     1024 RESIST <=       2 SUSC <=       1 SUSC  =   0.06 SUSC
WHO 2012 S-12.5 Salmonella Eko 4,12:e,h:1,6  >      32 RESIST <=   0.12 SUSC <=   0.03 SUSC  =   0.06 SUSC  =       8 SUSC  =    0.03 SUSC  <=     0.5 SUSC  =       4 SUSC  <=      8 SUSC  >     1024 RESIST  >      32 RESIST  >      32 RESIST  >      32 RESIST
WHO 2012 S-12.6 Salmonella Colindale 6,7:r:1,7 <=       1 SUSC <=   0.12 SUSC  =  0.125 SUSC  =   0.03 SUSC  =       8 SUSC  =    0.03 SUSC  <=     0.5 SUSC  =       2 SUSC  <=      8 SUSC  =       64 SUSC <=       2 SUSC <=       1 SUSC  =   0.03 SUSC
WHO 2012 S-12.7 Salmonella Give 3,10:l,v:1,7 <=       1 SUSC <=   0.12 SUSC  =  0.125 SUSC <=   0.03 SUSC  =       64 RESIST  =    0.25 RESIST  =     0.5 SUSC  >      64 RESIST  <=      8 SUSC  <=     16 SUSC  >      32 RESIST <=       1 SUSC  =   0.03 SUSC
WHO 2012 S-12.8 Salmonella Hillingdon 9,46:g,m:- <=       1 SUSC <=   0.12 SUSC  =   0.06 SUSC  =   0.03 SUSC  =       8 SUSC  =    0.03 SUSC  =     0.5 SUSC  =       8 SUSC  =       16 INTER  =       64 SUSC <=       2 SUSC <=       1 SUSC  =   0.03 SUSC
WHO 2012 SH-12.1 Shigella flexneri 6  =        4 SUSC <=   0.12 SUSC  =   0.06 SUSC  =   0.03 SUSC  =       4 SUSC  =    0.03 SUSC  =       1 SUSC  =       2 SUSC  <=      8 SUSC  <=     16 SUSC <=       2 SUSC <=       1 SUSC  =   0.03 SUSC
WHO 2012 SH-12.2 Shigella flexneri var X  >      32 RESIST <=   0.12 SUSC  =   0.06 SUSC  =   0.03 SUSC  =       64 RESIST  =        1 RESIST  =       1 SUSC  >      64 RESIST  =      128 RESIST  <=     16 SUSC  >      32 RESIST  >      32 RESIST  =   0.25 SUSC
WHO 2012 SH-12.3 Shigella flexneri 1a  >      32 RESIST <=   0.12 SUSC  =   0.06 SUSC  =   0.03 SUSC  =       64 RESIST  =        1 RESIST  =       1 SUSC  >      64 RESIST  >      128 RESIST  >     1024 RESIST  >      32 RESIST  >      32 RESIST  >      32 RESIST
WHO 2012 SH-12.4 Shigella flexneri 1b  =       2 SUSC <=   0.12 SUSC  =   0.06 SUSC  =   0.03 SUSC  >      64 RESIST  =    0.12 RESIST  =       2 SUSC  >      64 RESIST  =       32 RESIST  >     1024 RESIST  >      32 RESIST  >      32 RESIST  >      32 RESIST
WHO 2012 C-12.1 C. jejuni  =       8 SUSC  >       4 RESIST  =       1 SUSC  =    0.25 SUSC  >      64 RESIST  <=     1 SUSC  =      0.5 SUSC
WHO 2012 C-12.2 C. jejuni  =       8 SUSC  >       4 RESIST  >      32 RESIST  =    0.25 SUSC  >      64 RESIST  <=     1 SUSC  >      16 RESIST
WHO B-12.1 Salmonella Paratyphi B var. Java
TMP SXT
Trim/SulfaTrimethoprimAmpicillin Cefotaxime Ceftazidime Ceftriaxone Chloramphenicol
CIP GEN NAL STRAMP CTX CAZ
STR TET
Chloramphenicol Ciprofloxacin
Ciprofloxacin Gentamicin
CHL CIP ERY GEN NAL
CRO CHL
Nalidixic acid Streptomycin Sulfonamides Tetracycline
Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
SMX TET
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PROTOCOL for 
- serotyping and antimicrobial susceptibility testing of Salmonella  
- serotyping and antimicrobial susceptibility testing of Shigella  
- identification and antimicrobial susceptibility testing of Campylobacter  
- identification of an unknown enteric pathogen  
 
1 INTRODUCTION    ..................................................................................................................... 1
2 OBJECTIVES    ............................................................................................................................ 2
3 OUTLINE OF THE EQAS 2012    .............................................................................................. 2
3.1 Shipping, receipt and storage of strains    ........................................................................................ 2
3.2 Serotyping of Salmonella    .............................................................................................................. 3
3.3 Antimicrobial susceptibility testing of Salmonella, Shigella and Escherichia coli ATCC 25922    3
3.4 Handling the Campylobacter strains    ............................................................................................. 5
3.5 Identification of Campylobacter    ................................................................................................... 6
3.6 Antimicrobial susceptibility testing of Campylobacter and Campylobacter jejuni ATCC 33560   6
3.7 Identification of the unknown enteric pathogen    ........................................................................... 7
4 REPORTING OF RESULTS AND EVALUATION    .............................................................. 7
5     HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE    ................................ 8
 
1 INTRODUCTION 
In 2000, the Global Foodborne Infections Network (formerly known as WHO Global Salm-Surv) 
launched an External Quality Assurance System (EQAS). The EQAS is organized by the National 
Food Institute, Technical University of Denmark (DTU Food), in collaboration with partners and 
Regional Sites in WHO GFN.  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs, it is placed with a competent subcontractor and the National Food Institute is 
responsible for the subcontractor’s work. 
The WHO EQAS 2012 includes  
- serotyping and antimicrobial susceptibility testing of eight Salmonella strains,  
- serotyping and antimicrobial susceptibility testing of four Shigella strains,  
- antimicrobial susceptibility testing of the Escherichia coli ATCC 25922 (CCM 3954) 
reference strain for quality control,  
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- identification and antimicrobial susceptibility testing of two thermophilic Campylobacter 
isolates,  
- antimicrobial susceptibility testing of Campylobacter jejuni ATCC 33560 (CCM 6214) 
reference strain for quality control,  
- identification of one ‘unknown’ bacterial isolate.  
All participants will receive the strains according to the information they reported in the sign-up 
form.   
The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the WHO CC website (see 
www.antimicrobialresistance.dk). 
2 OBJECTIVES 
The main objective of this EQAS is to support laboratories to assess and if necessary improve the 
quality of serotyping and antimicrobial susceptibility testing of enteric human pathogens, especially 
Salmonella. A further objective is to assess and improve the comparability of surveillance data on 
Salmonella serotypes and antimicrobial susceptibility reported by different laboratories. Therefore, 
the laboratory work for this EQAS should be done by using the methods routinely used in your 
laboratory. 
3 OUTLINE OF THE EQAS 2012 
3.1 Shipping, receipt and storage of strains 
In August/September 2012 around 190 laboratories located worldwide will receive a parcel 
containing eight Salmonella strains, four Shigella strains, two Campylobacter strains and one 
‘unknown’ bacterial isolate (according to information reported in the sign-up form). An E. coli 
ATCC 25922 reference strain and a C. jejuni ATCC 33560 reference strain will be included for 
participants who signed up to perform antimicrobial susceptibility testing (AST) and did not receive 
them previously. All provided strains belong to UN3373, Biological substance category B. ESBL-
producing strains could be included in the selected material.  
 Please confirm receipt of the parcel through the confirmation form enclosed in the shipment.  
The Salmonella and Shigella strains, and the ‘unknown’ bacterial isolate are shipped as agar stab 
cultures whereas the reference strains and the Campylobacter strains are shipped lyophilised. On 
arrival, the agar stab cultures must be subcultured and prepared for storage in your strain collection 
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(e.g. in a -80°C freezer). This set of cultures should serve as reference if discrepancies are detected 
during the testing (e.g. they can be used if errors such as mis-labelling or contamination occur). 
Lyophilised strains must be reconstituted, and you can find below a suggested procedure. 
3.2 Serotyping of Salmonella  
The eight Salmonella strains should be serotyped by using the method routinely used in the 
laboratory. If you do not have all the necessary antisera please go as far as you can in the 
identification and report the serogroup, since also serogroup results will be evaluated. Serogroups 
should be reported using terms according to Kauffmann-White-Le Minor (Grimont and Weill, 2007. 
9th ed. Antigenic formulae of the Salmonella serovars. WHO Collaborating Centre for Reference 
and Research on Salmonella). 
Please fill in information concerning the brand of antisera used for typing in the fields available in 
the database for entering results. In addition, we kindly ask you to report which antisera you think is 
required to complete the serotyping, if relevant. 
3.3 Antimicrobial susceptibility testing of Salmonella, Shigella and Escherichia coli ATCC 
25922  
The Salmonella and Shigella strains as well as the E. coli ATCC 25922 reference strain should be 
tested for susceptibility towards as many as possible of the antimicrobials mentioned in the test 
form. Please use the methods routinely used
For reconstitution of the E. coli reference strain, please see the document ‘Instructions for opening 
and reviving lyophilised cultures’ on the WHO CC website (see 
 in your laboratory.  
www.antimicrobialresistance.dk). 
Testing of gentamicin and streptomycin susceptibility may be valuable for monitoring purposes. 
Therefore we kindly ask you to disregard, for the purpose of this proficiency trial, that the Clinical 
and Laboratory Standards Institute (CLSI) guidelines state that Salmonella and Shigella should not 
be reported as susceptible to aminoglycosides. 
The breakpoints used in this EQAS for interpreting MIC results are in accordance with CLSI 
values, and are supplemented with values from the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST, www.eucast.org) and DTU Food (Table 1). Consequently, 
interpretation of MIC results will lead to categorization of strains into three categories: resistant (R), 
intermediate (I) and susceptible (S). In the evaluation report that you receive upon result 
submission, you can find that obtained interpretations in accordance with the expected 
interpretation will be defined as ‘correct’, whereas deviations from the expected interpretation will 
be defined as ‘minor’ (I ↔ S or I ↔ R), ‘major’ (S interpreted as R) or ‘very major’ (R interpreted 
as S).  
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Please report the breakpoints that you routinely use in your laboratory for interpretation of 
antimicrobial susceptibility test results in the fields available in the database (or in the test forms). 
Concerning ciprofloxacin susceptibility test, please note that a low breakpoint has been used to 
determine the resistance category. This low breakpoint corresponds to the EUCAST 
epidemiological cut-off value, which was established to take into consideration mechanisms of 
resistance like qnr genes or one point-mutation in the gyrase gene (Table 1; www.eucast.org).  
In this EQAS, microorganisms showing reduced susceptibility to ciprofloxacin are considered 
ciprofloxacin-resistant. 
Table 1. Interpretive breakpoint for Salmonella and Shigella antimicrobial susceptibility testing 
Antimicrobials  Reference value, MIC (µg/mL) Reference value, Disk diffusion (mm) 
Sensitive Intermediate Resistant Sensitive Intermediate Resistant 
Ampicillin, AMP ≤8 16 ≥32 ≥17 14-16 ≤13 
Cefotaxime, CTX ≤1 - >1 >27 - ≤27 
Ceftazidime, CAZ ≤1 - >1 >22 - ≤22 
Ceftriaxone, CRO ≤1 - >1 >25 - ≤25 
Chloramphenicol, CHL ≤8 16 ≥32 ≥18 13-17 ≤12 
Ciprofloxacin, CIP <0.125* - ≥0.125* 
≥23mm 
(1µg)*** 
or 
≥30mm 
(5µg)*** 
- 
<23mm 
(1µg)*** 
or 
<30mm 
(5µg)*** 
Gentamicin, GEN ≤4 8 ≥16 ≥15 13-14 ≤12 
Nalidixic acid, NAL ≤16 - ≥32 ≥19 14-18 ≤13 
Streptomycin, STR ≤8** 16** ≥32** ≥15 12-14 ≤11 
Sulfonamides, SMX
 
  
≤256 - ≥512 ≥17 13-16 ≤12 
Tetracycline, TET ≤4 8 ≥16 ≥15 12-14 ≤11 
Trimethoprim, TMP ≤8 - ≥16 ≥16 11-15 ≤10 
Trimethoprim + 
sulfamethoxazole, 
TMP+SMX, SXT 
≤2/38 - ≥4/76 ≥16 11-15 ≤10 
Reference values used in this EQAS are according to CLSI, with the following exceptions:   
* EUCAST (epidemiological cut-off values)      
** DTU Food 
*** In the absence of values provided by EUCAST, the article by Cavaco LM and Aarestrup FM (J. Clin. 
Microbiol. 2009. Sep;47(9):2751-8) provides the background for these interpretative criteria in the WHO 
GFN EQAS. In that article, Shigella was not included. However, the same interpretative criteria are applied 
in this context. 
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The following tests for detection of Extended-Spectrum Beta-Lactamase (ESBL) production are 
optional.  
Important notes: beta-lactam resistance 
All strains showing reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ) and/or 
ceftriaxone (CRO) could be tested for ESBL production by confirmatory test. Confirmatory test for 
ESBL production requires use of both cefotaxime (CTX) and ceftazidime (CAZ) alone, and in 
combination with a β-lactamase inhibitor (clavulanic acid). Synergy is defined either as i) a ≥ 3 
twofold concentration decrease in an MIC for either antimicrobial agent tested in combination with 
clavulanic acid vs. its MIC when tested alone (E-test 3 dilution steps difference; MIC CTX : 
CTX/CL or CAZ : CAZ/CL ratio ≥ 8) or ii) a ≥ 5 mm increase in a zone diameter for either 
antimicrobial agent tested in combination with clavulanic acid vs. its zone when tested alone (CLSI 
M100 Table 2A; Enterobacteriaceae). The presence of synergy indicates ESBL production. 
Of note, MIC values and relative interpretation of cefotaxime (CTX), ceftazidime (CAZ) and/or 
ceftriaxone (CRO) used for detection of beta-lactamase-producing strains in this EQAS should be 
reported as found, which is in accordance with EUCAST expert rules. 
3.4 Handling the Campylobacter strains 
Freeze-dried cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule, and all instructions given below should be followed closely to ensure the safety of the 
person who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture written on the label. 
b. Make a file cut on the ampoule just above the shoulder of the ampoule. 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool. 
d. Crack the glass using sterile gauze or cotton to protect your fingers. 
e. Add to the dried suspension about 0.5 ml of appropriate broth or sterile 0.9% NaCl solution 
by using a pipette. Mix carefully to avoid creating aerosols.  
f. Inoculate the suspension on a suitable agar plate with a 10µl loop or a cotton swab.  
g. Transfer the rest of the content of the ampoule to a test tube containing 5-6 ml of a suitable 
liquid media. 
h. Incubate the agar plate and liquid media at a temperature of 42°C at microaerobic conditions 
for 24-48 hours. 
i. Inoculate a second agar plate from the liquid media with a 10µl loop or a cotton swab if the 
initial plate had inadequate growth. 
j. Select a pure culture with vigorous growth from the agar plate for further work. 
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Please note that:  
• Cultures may need at least one subculture before they can be optimally used  
• Unopened ampoules should be kept in a dark and cool place! 
For reconstitution of C. jejuni ATCC33560 reference strain, please see the document ‘Instructions 
for opening and reviving lyophilised cultures’ on the WHO CC website (see 
www.antimicrobialresistance.dk). 
3.5 Identification of Campylobacter  
The two thermophilic Campylobacter isolates should be identified to species level.  
3.6 Antimicrobial susceptibility testing of Campylobacter and Campylobacter jejuni ATCC 
33560 
The Campylobacter test strains and the C. jejuni reference strain should be tested for susceptibility 
to as many antimicrobials as possible among the ones mentioned in the test form. It should be noted 
that only MIC methods ( i.e. broth or agar dilution methods) are recommendable for AST of 
Campylobacter. Neither the use of disk diffusion nor E-test is recommendable for AST of 
Campylobacter.  
In this EQAS, the breakpoints used for interpretation of MIC results for Campylobacter are 
epidemiological cut-off values according to EUCAST (www.eucast.org; Table 2). Consequently, 
only two categories of characterisation (resistant, R or susceptible, S) are allowed. In the evaluation 
report that you receive upon result submission, you can find that obtained interpretations in 
agreement with the expected interpretation, will be categorised as ‘correct’, whereas deviations 
from the expected interpretation will be categorizes as ‘incorrect’.  
Please report the breakpoints that you routinely use in your laboratory for interpretation of 
antimicrobial susceptibility test results, in the fields available in the database (or in the test form).  
Note that the interpretation of antimicrobial susceptibility test results for Campylobacter requires 
knowledge of the Campylobacter species. If you did not sign-up for Campylobacter identification, 
but perform AST on Campylobacter, you are welcome to contact the EQAS Coordinator to obtain 
information regarding the identity of the Campylobacter test strains. 
The sub-cultured Campylobacter strains should be used for MIC-testing after incubation at 36-37ºC 
for 48 hours or at 42ºC for 24 hours. Likely, two subcultures are needed prior to MIC-testing to 
ensure optimal growth.  
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Table 2. Interpretive criteria for Campylobacter antimicrobial susceptibility testing 
Antimicrobials for Campylobacter MIC (µg/mL) R is > 
MIC (µg/mL) 
R is > 
 C. jejuni C. coli 
Chloramphenicol, CHL 16 16 
Ciprofloxacin, CIP 0.5 1 
Erythromycin, ERY 4 8 
Gentamicin, GEN 2 2 
Nalicixic acid, NAL 16 16 
Streptomycin, STR 4 4 
Tetracycline, TET 1 2 
Reference values for interpretation of Campylobacter AST results according to EUCAST 
 
3.7 Identification of the unknown enteric pathogen 
The ‘unknown’ isolate should be identified to species level and further typed if relevant.  
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the enclosed test forms and enter your results into the interactive web 
database.  
We recommend reading carefully the description in paragraph 5 before entering your results in the 
web database. For entering your results via the web, you will be guided through all steps on the 
screen and you will immediately be able to view and print a report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
Results must be submitted no later than 31 December 2012. 
If you do not have access to the Internet, or if you experience difficulties in entering your results, 
please return the completed test forms by e-mail, fax or mail to the National Food Institute, 
Denmark. 
All results will be summarized in a report which will be publicly available. Individual results will 
be anonymous and will only be forwarded to the official GFN Regional Centre in your region. 
If you have any questions or concerns, please do not hesitate to contact the EQAS 
Coordinator: 
Susanne Karlsmose (suska@food.dtu.dk) 
National Food Institute, Technical University of Denmark 
Kemitorvet, Building 204 ground floor, DK-2800 Lyngby - DENMARK 
Tel: +45 3588 6601, Fax: +45 3588 6341 
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It is possible to communicate with the EQAS organisers in other languages than English. However, 
this is not a direct contact with the EQAS organisers since translation of the message is required. 
The following languages may be used: Chinese, French, Portuguese, Russian and Spanish. 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read these instructions before entering the web page. Remember that you need by your side 
the completed test forms and the breakpoint values you used.  
In general, you navigate in the database with the Tab-key and mouse, and at any time a click on the 
WHO logo takes you back to the main menu. 
1) Enter the WHO CC website (from http://www.antimicrobialresistance.dk), then 
a. Click on ‘EQAS’ 
b. Click on the link for the interactive database 
c. Write your username and password in lower-case letters and click on ‘Login’. 
You can find your username and password in the letter accompanying your parcel.  
Your username and password will remain unchanged in future trials. 
2) Click on ‘Materials and methods’  
a. Fill in the fields relative to brand of antisera (very important because we would like to 
compare results obtained with different brands of antisera) 
b. Fill in the fields relative to the method used for antimicrobial susceptibility testing 
c. Enter the brand of materials, e.g. Oxoid 
d. Fill in the field asking whether your institute serves as a national reference laboratory  
e. In the comment field, report which antisera you think is required to complete your 
serotyping, if relevant 
f. Click on ‘Save and go to next page’ – REMEMBER TO SAVE EACH PAGE BEFORE 
LEAVING IT! 
3) In the data entry page ‘Routinely used breakpoints’ 
a. Fill in the fields relative to the breakpoints used routinely in your laboratory to determine 
the antimicrobial susceptibility category. Remember to use the operator keys in order to 
show – equal to (=), less than (<), less or equal to(≤), greater than (>) or greater than or 
equal to (≥). 
4) In the data entry pages ‘Salmonella strains 1-8’, 
a. SELECT the serogroup (O-group) from the drop-down list, DO NOT WRITE – Wait a few 
seconds – the page will automatically reload, so that the drop-down list in the field 
“Serotype” only contains serotypes belonging to the chosen serogroup.  
b. SELECT the serotype from the drop-down list – DO NOT WRITE – wait a few seconds 
and you can enter the antigenic formula (e.g. 1,4,5,12:i:1,2)  
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c. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator 
keys to show e.g. equal to (=), etc.  
d. Enter the interpretation as R (resistant), I (intermediate) or S (susceptible) 
e. If you performed confirmatory tests for ESBL production, please choose the appropriate 
result from the pick list. 
f. If relevant, fill in the field related to comments (e.g. which antisera you miss for complete 
serotyping)  
g. Click on ‘Save and go to next page’ 
If you did not perform these tests, please leave the fields empty  
5) In the data entry page ‘E. coli reference strain’: 
a. Enter the zone diameters in mm or MIC values in µg/ml. Remember to use the operator 
keys to show e.g. equal to (=), etc. 
b. Click on ‘Save and go to next page’ 
6) In the page ‘Identification of Campylobacter and unknown sample’:  
a. Choose the correct Campylobacter species from the pick list 
b. Fill in the field concerning species and type of the unknown bacterial isolate, and report the 
method used for identification 
c. Click on ‘Save and go to next page’ 
If you did not perform these tests, please leave the fields empty 
7) The next page is a menu that allows you to review the input pages and approve your input and 
finally see and print the evaluated results 
a. Browse through the input pages and make corrections if necessary. Remember to click on 
‘save and go to next page’ if you make any corrections. 
b. Approve your input. Be sure that you have filled in all the results before approval, as .YOU 
CAN ONLY APPROVE ONCE!. The approval blocks your data entry into the interactive 
database, but allows you to see the evaluated results. 
c. As soon as you have approved your input, an evaluation report will appear.  
8) After browsing all pages in the report, you will find a new menu. You can choose ‘EQAS 2012 
start page’, ‘Review evaluated results’ (a printer friendly version of the evaluation report is also 
available) or ‘Go to Global Salm-Surv homepage’.   
End of entering your data – thank you very much! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
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WEEKLY MIC QC CHART 
 
 
Reference: CLSI M7-A8, page 45 
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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